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Abstract 
 
Intermittent fasting (IF) is a recently popularized meal timing strategy whereby 
individuals abstain continuously from any energy intake for 16 to 20 hours each day, 
subsequently condensing energy intake into a short period spanning 4 to 8 hours. We aimed to 
test the effects of intermittent fasting in 10 individuals with Type 2 Diabetes Mellitus in 
conjunction with recommendations to consume a high protein diet in a 6 to 8 week withdrawal 
study. This study consisted of three phases: baseline, intervention, and follow-up.  During the 2-
week baseline and intervention phases participants consumed meals at regular times. 
Biochemical, anthropometric, and physical activity measurements were taken at the end of each 
phase. Participants reported morning, afternoon and evening self-monitored blood glucose and 
fasting duration on a daily basis, in addition to completing a remote food photography diary three 
times within each study phase. Despite the short duration of the intervention phase, intermittent 
fasting led to significant decreases in weight, BMI, morning SMBG, and overall reductions in 
waist circumference, C-reactive protein, energy intake, carbohydrate intake, and fat intake. There 
were significant variations between participants in response to intermittent fasting in respect to 
changes in lipids and insulin sensitivity, which could not be explained by baseline biochemical 
or anthropometric measures, fasting duration, energy intake, or physical activity. Upon cessation 
of intermittent fasting, biochemical changes regressed towards baseline values during the follow-
up period. Intermittent fasting was well tolerated by most participants, and no severe adverse 
events were noted. Morning nausea was the most common complaint, which abruptly ceased 
when medication timing was changed.   
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CHAPTER 1 
LITERATURE REVIEW 
 
1.1 Introduction 
 As of 2010, diabetes mellitus (DM) afflicts more than 285 million adults between the 
ages of 20 to 79 worldwide, with this number expected to grow to 439 million adults by 2030 
(1). Within Canada, 2.4 million individuals have been diagnosed with diabetes, with this number 
expected to rise to 3.7 million by 2019 (2). Diabetes contributes significantly to increased rates 
of cardiovascular disease, renal disease, retinopathy, and limb amputations within Canada (2). 
This translates into an increased cost burden on the Canadian health care system. Individuals 
afflicted with diabetes require three to four times the amount of medical resources compared to 
those without diabetes (2).  
Diabetes can be categorized as Type 1, Type 2, or Gestational. The high incidence of 
diabetes is due primarily to Diabetes Mellitus Type 2 (DM2), which accounts for over 90% of all 
new diagnoses of diabetes (3). Diabetes Mellitus Type 1 (DM1) differs from DM2, as it is 
predominantly diagnosed in adulthood and often does not result in the complete and ongoing 
destruction of pancreatic beta cells. Roy Taylor has put forth the ‘Twin Cycle Hypothesis’ to 
explain the etiology of DM2 (4). Dr. Taylor postulates that the accumulation of hepatic and 
pancreatic fat is the primary driver of DM2, as it results in reduced hepatic and peripheral insulin 
sensitivity and diminished insulin secretion. These changes then trigger chronic uncontrolled 
hyperglycemia and further deterioration of hepatic and pancreatic function (4). Taylor attributes 
this accumulation of hepatic and pancreatic fat in DM2 to chronic positive energy balance (4). 
As such, the pathophysiology of DM2 arises from the triad of relative insulin deficiency, excess 
hepatic glucose output, and to a lesser extent, peripheral insulin resistance. DM1 is an 
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autoimmune disorder beginning primarily in childhood where pancreatic beta cells are destroyed 
by the innate immune system. DM1 and DM2 have very little in common as far as causal factors 
may explain; however, both conditions lead to chronic hyperglycemia and its accompanying 
comorbidities, such as renal, retinal, and vascular damage.     
 
1.2 Health Markers in the Diagnosis and Management of DM2 
1.2.1 Biochemical Measurements 
1.2.1.1 Plasma Glucose and Glycemic control  
A diagnosis of DM2 is achieved by direct and indirect assessment of circulating plasma 
glucose levels. There are three primary measures of glycemic control in DM2 – Fasting Plasma 
Glucose (FPG), Oral Glucose Tolerance Test (OGTT), and Glycated Hemoglobin (HbA1c). 
Plasma glucose is measured directly by FPG or an OGTT. The amount of circulating glucose in 
plasma after an 8h-14h overnight fast is defined as FPG. An OGTT is a measurement that 
reflects the amount of circulating glucose in plasma 2h after a 75g oral bolus of glucose is 
consumed. HbA1c reflects the percentage of glycated hemoglobin, which acts as an indirect 
measurement of average glucose levels of the preceding 3-month period. A diagnosis of DM2 is 
made when symptomatic hyperglycemia and any one of the following criteria are met: FPG > 
7.0mmol/L, OGTT > 11.1mmol/L, or HbA1c > 6.5% (5). In the absence of symptomatic 
hyperglycemia, repeat testing on a separate day is performed. Lastly, a random plasma glucose 
(RPG) level > 11.1 mmol/L, which directly assesses circulating levels of glucose at a random 
time of day, can be used to justify additional testing methods but should not be used to confirm a 
diagnosis of DM2. 
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After diagnosis, most individuals with DM2 are advised to reach a HbA1c below 7.0%, 
FPG 4.0-7.0mmol/L, and post-prandial glucose levels of 5.0-10.0mmol/L, as this is associated 
with the reduction of micro- and macrovascular complications, and improved mortality outcomes 
(6–8). There is considerable debate that achieving a HbA1c < 6.5% is beneficial, as a recent 
meta-analysis of all major DM2 trials indicates that intensive diabetes treatment demonstrates 
limited benefits with significant increases in all-cause mortality and cardiovascular death end-
points, as well as occurrences of severe hypoglycemia (9). Fortunately, clinicians are able to 
individualize treatment and glycemic targets for at-risk patients in order to reduce the risk of 
complications.  
A fifth measure of glycemic control, Self-Monitored Blood Glucose (SMBG), is acquired 
when patients monitor their serum glucose levels with the use of a portable glucometer and 
logbooks. In rare circumstances, SMBG can be used in place of HbA1c to observe daily 
glycemic control when confounders compromise HbA1c measurements. However, in most 
circumstances SMBG remains as a separate and adjunctive tool of monitoring glycemic control 
alongside HbA1c (10). SMBG is an effective method to confirm and monitor the treatment of 
hypoglycemia in individuals with diabetes, and can be a modestly effective tool alongside 
behavioural modification for glycemic control – but only with exceptional adherence and 
supervision from a health care professional (10,11). With decreasing levels of HbA1c, 
postprandial glycemia becomes a larger proportion of average glucose levels, and SMBG can be 
used to accurately capture these glycemic excursions in well-controlled individuals with DM2 
(12).  
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1.2.1.2 Insulin Resistance 
 Insulin resistance is a measure of the peripheral and hepatic incapacity to respond to 
circulating insulin, a primary feature of DM2. Peripheral and hepatic insulin resistance are 
independent and cumulative contributors to hyperglycemia in diabetes (13). Hepatic insulin 
resistance (via elevated hepatic glucose production) is one of the primary contributors to 
hyperglycemia in DM2, since peripheral tissues contribute approximately 20% of glucose 
disposal in the fasting state in those with DM2 (14).  The restoration of hepatic insulin sensitivity 
and reduction in the rate of hepatic gluconeogenesis occurs during the reversal of DM2 from a 
hypocaloric diet (15).   
The current gold standard in directly measuring insulin resistance is through the use of 
the hyperinsulinemic euglycemic clamp technique (16). The clamp technique involves a constant 
infusion of insulin of 5 to 120 mU·m
−2
·min
−1
 with boluses of dextrose infused at 5 to 10 minute 
intervals aided by a bedside glucose monitor to maintain euglycemia. Insulin sensitivity (SI) is 
then assessed by the formula SIClamp = M/(G × ΔI) – where M is the rate of glucose disposal, G is 
the steady state blood glucose concentration, and ΔI represents the difference between fasting 
plasma insulin and steady state insulin (16). The hyperinsulinemic steady state suppresses 
hepatic gluconeogenesis, which demonstrates a direct comparison of the rate of peripheral 
glucose disposal relative to plasma insulin concentrations. Exogenous insulin from the 
hyperinsulinemic state controls for the effects of endogenous pro-insulin, giving a more direct 
view of insulin sensitivity (17). The main limitations of the hyperinsulinemic euglycemic clamp 
technique are time, labor cost, and lack of access to the general population. The supra-
physiological levels of insulin remain a concern, as it may have systemic effects on glucose 
disposal and hepatic gluconeogenesis not present in normal physiological conditions. 
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Another direct test of insulin sensitivity is the Insulin Suppression Test (IST). IST 
involves a participant being administered an oral insulin suppressor followed by constant insulin 
and glucose infusion for 3 hours. The IST has similar limitations, validity, and reliability as the 
clamp technique but with fewer technical demands. However, the risk of hypoglycemia and 
hyperglycemia are increased in select populations during IST (16).  
The only indirect method of assessing insulin resistance is the Frequently Sampled 
Intravenous Glucose Tolerance Test (FSIVGTT). The FSIVGTT involves a single intravenously 
administered bolus of glucose followed by plasma glucose and insulin measurements taken 
continuously for 3 hours. The FSIVGTT oversimplifies glucose homeostasis and does not match 
the validity of direct methods, yet is as labor intensive as the direct methods (16). 
Surrogate index measures of insulin resistance derived from measures of insulin and 
glucose in the fasting state include log fasting insulin, glucose/insulin ratio, Homeostasis Model 
Assessment (HOMA-IR), log HOMA-IR, and Quantitative Insulin Sensitivity Check Index 
(QUICK1). The HOMA-IR, calculated by ([fasting insulin (μU/ml)] × [fasting glucose 
(mmol/l)])/22.5, has the best agreement with the clamp technique in assessing insulin resistance 
in individuals with DM2 (18). Log fasting insulin and glucose/insulin ratio are the poorest 
measures of insulin resistance in individuals with DM2 (16). QUICK1 has been shown to be 
inferior to HOMA-IR with respect to their agreements with the clamp technique, but superior in 
reproducibility in individuals with DM2 (18). Unfortunately index and indirect measures suffer 
from confounded results due to the effect of pro-insulin on fasting insulin values (17).  
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1.2.1.3 Inflammation 
Chronic low-grade inflammation has recently been implicated in the development of 
DM2, but the specific role of inflammation in the causation of DM2 has yet to be fully 
established (19). C-Reactive Protein (CRP), an acute phase protein, is the most widely used 
biomarker of inflammation. Elevated levels of CRP are indicative of non-specific systemic 
inflammation in multiple disease states. The synthesis of CRP occurs in the liver and is triggered 
by circulating cytokines released primarily by macrophages (20) as well as other immune cells 
(21). CRP then migrates towards and attaches to necrotic cells, where it exercises both pro- and 
anti-inflammatory effects (20). Interleukin-6 is primarily responsible for the synthesis of CRP 
(20). However, there are interactions between Interleukin-6, Interleukin-1-Beta, and other 
cytokines on the transcription and synthesis of CRP (20). Therefore, these cytokines are not as 
accurate as CRP for describing systemic inflammation or predicting the development of DM2 
(22,23). Within individuals with DM2, elevated levels of CRP have been independently 
associated with the progression of nephropathy (24), elevated fasting glucose, insulin resistance, 
and vascular dysfunction (25). CRP is subsequently lowered by exercise (26,27), oral diabetes 
medications (28), and dietary therapy (29). 
Other inflammatory biomarkers have been used in research settings to describe chronic 
inflammation in DM2. Yet do not have the evidence from large trials to establish relationships 
regarding the onset and progression of DM2 (19). These include interleukins, tumour necrosis 
factor-alpha, cortisol, ferritin, serum amyloid a, sialic acid, and a1-acid glycoprotein. 
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1.2.1.4 Chronic Kidney Disease 
 In 2009, 34% of Chronic Kidney Disease (CKD) cases were attributed to diabetes and 
individuals with diabetes were 12 times more likely than non-diabetics to be hospitalized with 
end stage renal disease (2). Glomerular Filtration Rate (GFR) is a measure of the amount of 
blood that passes through the glomeruli of the kidneys each minute (expressed as 
ml/min/1.73m
2
), and is a common and effective measure for determining kidney function. As 
such, GFR is used to stratify CKD progression: Stage 1 or normal kidney function (GFR>89), 
Stage 2 or mild kidney damage (GFR 60-89), Stage 3 or moderate kidney damage (GFR 30-59), 
Stage 4 or severe kidney damage (GFR 16-29) and Stage 5 or end-stage renal disease (GFR < 
16) (30).  Creatinine is a standard marker of kidney function used commonly while monitoring 
CKD progression in DM2 (30) and is used in several formulas to estimate GFR. A static measure 
of plasma creatinine (when accompanied by age, sex, and race) is put into the Modification of 
Diet by Renal Disease equation (MDRD) and used to estimate GFR with sufficient accuracy 
(albeit a tendency to over-diagnose CKD) in both healthy populations and individuals with CKD 
when compared to measured iothalamate clearance (31). Additionally, a combination of urinary 
creatinine, urinary flow rate, and plasma creatinine over a 24-hour period can determine 
Creatinine Clearance (CCR). CCR refers to the amount of creatinine that is cleared from blood 
over a 24-hour period, which can be used as an indirect measure of GFR (32). CCR is routinely 
estimated in standard medical laboratories by inputting static measures of serum creatinine, age, 
and bodyweight into the Cockgroft-Gault formula (33).  
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1.2.2 Anthropometric Measurements 
1.2.2.1 Weight and Body Mass Index 
 Weight and Body Mass Index (BMI) are standard clinical tools used to classify patients 
as underweight, normal weight, overweight, or obese (34). Weight and BMI are used in many 
research and clinical settings to demonstrate the effect of lifestyle treatment on obesity and its 
comorbidities (7,35,36). BMI is defined as weight (kg)/height
2
 (m), and is commonly used in 
research and clinical settings to classify adiposity and disease risk in patients (37). A BMI of < 
18.5 kg/m
2
 is considered underweight, >= 25.0 kg/m
2
 as overweight, and >= 30.0 kg/m
2
 as obese 
(34).  
 
1.2.2.2 Waist Circumference 
 Waist Circumference (WC) is a measurement of central adiposity used to assess disease 
risk irrespective of weight or BMI. According to the Canadian Medical Association’s guidelines 
on screening in overweight and obese patients, WC is an accurate estimator for the risk of the 
patient developing DM2, dyslipidemia, hypertension, and the metabolic syndrome (34). Waist 
circumference has superior validity compared to BMI in predicting individuals at risk for 
developing DM2, and superior validity compared to Waist-to-Hip ratio (37) .Waist 
circumference has been shown to decrease during weight loss from diet, exercise, and some 
medications in individuals with DM2, coinciding with improvements in glycemic control 
(7,35,36). A recent demonstration has shown that WC can be an extremely accurate predictor of 
the reversal of insulin resistance after bariatric surgery (38).  Cut-offs for WC are >102cm for 
men and >88cm for women; dependent on ethnicity, age, and size (34). 
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1.2.2.3 Body Composition 
  Hydro-densitometry, where an individual is submersed underwater to measure body 
density and then an estimation of body fat is made using the Brozek or Siri Formula, is 
considered the gold-standard of body composition analysis (39). Dual X-Ray Absorptiometry 
(DEXA) is considered to be on par with the validity and reliability of Hydro-densitometry (39), 
but remains costly and requires technical expertise. Air-Displacement Plethysmography (ADP) is 
a commonly used method for analyzing body composition with accuracy comparable to Hydro-
densitometry and DEXA, but with wider error ranges and imperfect correlations (39,40). Other 
methods of body composition, such as Bioelectrical Impendence Analysis (BIA) and Skinfold 
Measurements are more affordable, but suffer from considerable error and show questionable 
reliability and validity (41).  
 
1.3 Capturing Dietary and Exercise Habits in DM2 
1.3.1 Assessment of Physical Activity 
 Capturing physical activity habits for research purposes remains a significant challenge, 
with no methods showing clear superiority over others (42). Currently, there are several methods 
of assessing physical activity in free-living adults. Monitoring devices worn daily, such as two 
and three-dimensional accelerometers and pedometers are acceptable methods of tracking 
physical activity in free-living adults. Accelerometers are currently the gold standard in assessing 
physical activity in free-living adults (43), however they present many logistical hurdles in 
implementation, and may underestimate or omit certain types of physical activity (42). Effective 
implementation of accelerometry requires knowledgeable and sufficiently trained technicians, 
pre-experimental testing for validity and reliability of accelerometers, equipment and software 
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for analysis and data-acquisition, and most importantly, ideal participant compliance in order to 
implement these methods effectively. 
 A more simple and common form of measuring activity in free-living adults is through 
questionnaire. Although physical activity questionnaires have concerns with validity and 
reliability (43) they do show sufficient test-retest reliability (44,45). In particular, the Yale 
Physical Activity Survey (YPAS) has shown sufficient accuracy when compared to the doubly 
labelled water method (a measure of total caloric expenditure), outperforming even some 
monitoring devices in group analysis (43,46). 
 Importantly, the primary purpose of tracking physical activity in a repeated measures 
clinical trial is to control for outliers who may increase or decrease their physical activity 
throughout the study period. The YPAS has considerable test-retest reliability that is suitable for 
a repeated measures design with free living-adults (44,45). 
 
1.3.2 Assessment of Dietary Intake 
 In Dr. Ioannidis’ recent BMJ paper entitled Implausible Results in Human Nutrition 
Research, he states: 
“Nutritional intake is notoriously difficult to capture with the questionnaire methods used 
by most studies. A recent analysis showed that in the National Health and Nutrition 
Examination Survey, an otherwise superb study, for two thirds of the participants the 
energy intake measures inferred from the questionnaire are incompatible with life.” (47) 
Dr. Ioannidis’ assertions are supported in validity and reliability tests for most written measures 
of dietary intake against the Doubly-Labelled Water method (DLW), the gold standard in 
measuring energy intake (48). In his paper, Dr. Ioannidis continues by berating even the most 
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technologically advanced methods of assessing dietary intake in free-living individuals, stating 
that they too have had abysmal results – supported by a single paper with limited scope (49). In 
his brief commentary Dr. Ioannidis overlooked the literature on a technique that has shown 
considerable efficiency and accuracy in capturing dietary intake, digital photography - namely 
the Remote Food Photography Method (RFPM). In 24h-recalls, written food diaries (weighed 
and un-weighed), and food frequency questionnaires, energy intake is consistently under-
reported (up to -59% of actual energy intake) when compared to DLW in free-living adults (48). 
In comparison, the RFPM has consistently shown only modest or no under-reporting of energy 
intake in both laboratory and free-living situations up to six days in duration against meals with 
known caloric content and the DLW method, respectively (50,51). When free-living adults were 
sent customized prompts in order to remind them to take photographs of food regularly, RFPM 
was not significantly different from DLW (mean energy intake of -3.7% [p-value = 0.16] vs. 
DLW).  
 
1.3.3 Assessment of Dietary Compliance, Hunger, and Satiety 
 Dietary intake records (as described in the previous section) are the general standard of 
assessing dietary compliance in most nutrition research. Satisfaction and tolerability of nutrition 
interventions remain greater challenges. In one study, a 30-item satisfaction questionnaire to 
assess dietary satisfaction was developed and tested prior to the study period. During validation, 
it was found that all items on the questionnaire correlated strongly with one simple visual analog 
scale (VAS):  
“Rate your overall satisfaction with the way you are eating” 
EXTREMELY DISLIKE   1   2   3   4   5   LIKE VERY MUCH 
 12 
This visual analog scale was then adopted as the only measure of dietary satisfaction within that 
study, as it correlated strongly to adherence in participants (52). To date, only one questionnaire 
has been validated specifically for use in those with DM2 – the Diabetes Dietary Satisfaction and 
Outcomes Measure (DDSOM) (53).  The DDSOM is a 47-item questionnaire assessing a range 
of perceptions using a 5-point VAS. Twenty-three items are dedicated to dietary satisfaction and 
ability to follow dietary recommendations, while the remaining items assess strategies for 
following dietary recommendations and the barriers to adhere to those meal plans. Satisfaction as 
determined by the DDSOM correlated strongly to adherence and lower HbA1c values in 
participants following meal plans and general dietary recommendations from dieticians (53). 
However, it remains to be seen if the DDSOM can be adapted to a broad range of dietary 
therapies, or simply standard medical nutrition interventions – as many of items on the 
questionnaire were specific to certain recommendations.   
 Hunger and satiety have been routinely measured in many dietary studies with the use of 
a VAS. VAS for hunger and satiety can be used to predict subsequent meal intake, act as a 
complementary measure when accounting for energy intake, can be manipulated in response to 
experimental changes in dietary habits, and show strong test-retest reliability within individuals 
in controlled settings (54–56). VAS for hunger and satiety can vary in their appearance and 
rating scale, although they are typically 100mm in length. Some VAS use numbers with 
corresponding descriptions while others use only descriptions with no corresponding numbers. 
Hunger and satiety are often measured by several VAS relating to hunger (prior to meal), 
stomach fullness (after meal), and motivation to continue eating (after meal) (55–58). It is 
important to note that these are purely subjective measures that are greatly impacted by social, 
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emotional, and cognitive factors and may not always accurately depict physiological hunger and 
satiety in free-living conditions as a result of an experimental dietary intervention. 
 
1.4 Common Pitfalls of Medical Nutrition Interventions in DM2 
 Current guidelines for nutritional intervention in the management of individuals with 
DM2 come from the Canadian Diabetes Association (CDA), which promotes the use of the 
Canada Food Guide. As such, the CDA promotes the use of calorie and macronutrient counting, 
food grouping, portion control, and the glycemic index for the management of DM2 – all dietary 
practices that require a certain level of baseline knowledge, skills, and dedication that many 
people with DM2 are often unable to understand, acquire and implement (59). Even a dietary 
skill as fundamental as counting calories led to a significant increase in self-perceived 
psychological stress, and subsequently increased midday and evening cortisol levels – effects not 
seen when participants restricted calories unintentionally (60,61). Increasing cortisol levels 
through either cortisol administration (62) or psychological stress (63) have been shown to 
increase ad lib caloric intake. The effect of broad spectrum psychological stress on increased 
food intake is specifically enhanced in people intentionally trying to restrict food intake (64). An 
innumerable amount of practical barriers await individuals with DM2 who clearly understand 
nutrition recommendations.  
There are additional barriers in the translation of nutrition guidelines for individuals who 
do not clearly understand nutrition. Behavioral obesity treatment applied by primary care 
physicians often do not result in significant weight loss (65). Considering health care workers 
may not have a more complete understanding of nutrition guidelines when compared to the 
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general population (66), it is understandable why such interventions are at best marginally 
effective.  
Direct consultations with dieticians are more promising, as they have shown to lead 
modest reductions in fasting glucose and HbA1c (67). However, there are significant barriers 
that regularly prevent patients from attending diabetes self-management programs (68). Even 
when given a descriptive meal plan by a registered dietician, individuals with DM2 often do not 
follow these plans because of their difficulty to implement and because of the explicit restriction 
of food choices (69).  
Individuals with DM2 list frustration, helplessness, unpredictable glycemic control, and 
continued disease progression as a primary barrier to motivation and continued adherence – 
despite adherence past recommendations (59).  The outlook can be bleak for individuals with 
DM2. The UKPDS study showed that 75% of newly diagnosed individuals with DM2 required 
additional therapeutic interventions after nine years of intensive treatment with diet, insulin, 
sulfonylureas or metformin. Moreover, only 8-42% of individuals were able to achieve the 
glycemic targets at any point in the UKPDS study (7). One cannot blame individuals with DM2 
for their negative outlook and inability to self-manage their disease. However, the current 
paradigm that emphasizes management over reversal is a likely cause of the inevitable 
progression of DM2. 
Multiple studies have confirmed a relevant finding: DM2 is reversible in the majority of 
patients through diet alone. Previous trials with simple and aggressive recommendations (i.e. 
600-1200 kcal/day with meal replacements and vegetables) that achieved moderate weight loss 
(15), or induced an acute energy deficit without significant weight loss (70) resulted in a 
complete reversal of DM2. These studies demonstrated that a very low-calorie diet is effective at 
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reversing DM2 but, with dropout rates in excess of 20%, leave much to be desired in terms of 
adherence and tolerability. 
 Simple nutritional interventions (interventions that do not require extensive training) have 
been used in the past to significantly improve outcomes in other disease states. The Lyon Diet 
Heart Study tested the effects of the Mediterranean Diet (explained in only a single 1-hour 
education session to participants) on cardiovascular outcomes in patients recovering from 
myocardial infarction and demonstrated a significant reduction in the re-occurrence of coronary 
events (71). It’s important to note that the Mediterranean Diet as it was taught in this study 
required minimal patient education and guidance, did not advocate any skill based dietary habits 
(calorie counting, glycemic index, etc.) and only made very broad, sweeping, and generalized 
guidelines for dietary behaviors. Individuals with DM2 are in desperate need of similarly 
effective and simple nutritional interventions for the reversal and prevention of DM2, but that 
address specific issues in those with DM2. 
 
1.5 Effects of Fasting 
1.5.1 Prolonged Fasting, Diurnal Variations, and Dietary Intake in DM2 
In the memoirs of Dr. George Cahill entitled “Fuel Metabolism in Starvation”, which 
summarized a lifetime of medical research on starvation, fasting, and diabetes, Dr. Cahill notes:  
“We also fasted two type 2 diabetics, who differed from [healthy patients] by better 
nitrogen conservation. They were slightly more efficient, in keeping with the concept of 
James Neel (at Michigan) that type 2 diabetes may have been an evolutionary selective 
advantage in a starving population”. (72) 
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These results were subsequently supported, in that individuals with DM2 were shown to produce 
more ketones in response to starvation, indicating that they were more efficient at producing the 
most dense and efficient energy substrate during starvation (73). Faiman & Moorhouse (73) also 
noticed a significant diurnal rhythm under fasting conditions now commonly referred to as “The 
Dawn Phenomenon”, where a dramatic increase in fasted morning glucose levels is observed. 
The Dawn Phenomenon has since been observed in studies on individuals with DM2 (74). The 
Dawn Phenomenon is generally attributed to a morning increase in cortisol. An experimental 
administration of the cortisol inhibitor metyrapone resulted in a decrease of plasma cortisol and 
blood glucose during a 12h fasted morning test in those with DM2 (75), and hyperglycemia is 
routinely observed in those who suffer from hypercortisolism (76). It has also been observed that 
lean patients with DM2 and glucose intolerance had an enhanced sensitivity to cortisol, which 
contributed significantly to hyperglycemia (77). Although healthy non-diabetic individuals 
experience an increase in morning fasted cortisol, this is attenuated by an increase in insulin 
secretion in healthy individuals but not in those with DM2 (78,79). It has also been observed that 
cortisol administration suppresses peripheral and hepatic insulin sensitivity, even in healthy 
individuals (80).  Given the interaction between glucose, insulin, and cortisol, is it reasonable to 
infer that time of day may affect the metabolic response to meal ingestion in individuals with 
DM2? 
It has been routinely observed that healthy individuals are most insulin sensitive in the 
morning (81) and when fed breakfast (82), with worsening glucose tolerance during the evening 
(81,83). Despite the results of acute observational studies, randomized control trials in healthy 
individuals testing breakfast inclusion or omission have had mixed results (84). In those with 
DM2, one of the few trials controlling for total caloric intake demonstrated that consuming 70% 
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of daily calories after 1900h resulted in lower 24h insulin and glucose concentrations and 
improved insulin sensitivity, with no abnormal elevation in night time and morning fasted 
glucose on the following day (85). Individuals with DM2 studied with the hyperglycemic clamp 
showed a very clear diurnal rhythm: insulin sensitivity reached a peak at 7PM and a nadir in the 
morning at 8AM. Insulin sensitivity was inversely related to measures of cortisol and free fatty 
acid, which both showed clear diurnal rhythms as well (86). Additionally, it was shown that a 
snacking meal pattern (3 meals + 3 snacks a day) led to greater mean 24h serum glucose when 
compared to less frequent (3 meals per day) meal intake (85). However, 3 meals with snacks is a 
first line nutrition recommendation from the Canadian Diabetes Association for the management 
of DM2 (87). A previous trial has demonstrated the difficulty of managing morning 
hyperglycemia in individuals with DM2. It was shown that the largest glucose excursions 
occurred in between the time of breakfast and lunch in individuals with DM2 irrespective of 
BMI, HOMA, HbA1c, and B-cell function (88). These striking observations highlight that 
alternative meal timing strategies have the potential to greatly influence glucose levels and in 
turn impact the development of chronic complications in those with DM2 over that of the 
currently recommended dietary strategy in DM2 management.  
 
1.5.2 Review of Intermittent Fasting Clinical Trials 
 One simple dietary intervention is Intermittent Fasting (IF), whereby caloric intake is 
restricted to a specific window of time followed by feeding within a restricted window of time. 
There are many variations of IF. One popularized method of IF restricts caloric intake for 18 to 
20 hours per day with unrestricted zero-calorie water, coffee and tea intake permitted during this 
time. This method includes a 4-6 hour ad libitum feeding period, typically during midday or 
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evening, that emphasizes high protein intake. This version of IF is particularly interesting 
because meal intake occurs during the periods of time when those with DM2 reach a diurnal 
peak in insulin sensitivity, and fasting occurs when cortisol and free fatty acids are at their 
diurnal peaks. Similar protocols have been studied (57,58,89,90) in non-diabetic populations 
with beneficial effects on insulin-mediated glucose uptake, improved insulin inhibition of 
lipolysis, reduced basal cortisol levels, loss of body fat, and increases in the anti-diabetic 
hormone adiponectin – all in the absence of caloric restriction and/or weight loss. Under 
metabolic ward conditions, participants felt too full when trying to consume an entire day’s 
worth of calories in the 4 hour feeding window, so much so that participants still lost a marginal 
amount of weight despite active encouragement from staff to eat more (57,58). This lends 
credibility to the hypothesis that IF would create a spontaneous energy deficit in free-living 
conditions when practiced consistently, a necessity for the reversal of DM2 (4). However, one 
study did note that morning FPG, glycemic control, and first phase insulin secretion during an 
OGTT worsened after 1 month of eucaloric IF (58). The health effects of IF in healthy 
individuals or those with DM2 have yet to be fully understood. 
The popular media and the medical community have been recently discussing the 
potential of IF to prevent or treat cardiovascular disease and DM2 (91). However, only two trials 
have assessed the effects of IF in individuals with DM2. One multi-day randomized crossover 
trial compared the effects of three dietary intake patterns with equal energy intake, low-fat 
breakfast + lunch vs. low-carbohydrate breakfast + lunch vs. fasting + Mediterranean-style lunch 
(92). The Mediterranean lunch resulted in glucose, insulin, and triglyceride excursions 
comparable to the low-fat lunch, similar triglyceride excursions compared to the low-
carbohydrate lunch, and enhanced GIP excursions compared to both the low-fat and low-
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carbohydrate lunches. However, due to the extended morning fast, the fast + Mediterranean 
lunch condition resulted in overall decreases in glucose and insulin concentrations despite energy 
intake being equalized. Results of a 3-month randomized crossover IF trial on individuals with 
DM2 had participants consume their meals in the morning and early afternoon, while abstaining 
from caloric intake for the remainder of the day (93). Compared to a standard hypocaloric diet, 
the IF diet showed a superior decrease in HbA1c, superior response to an OGTT, as well as 
superior decreases in FPG and morning fasted glucagon that correlated strongly to a superior 
decrease in overall hepatic fat content. Although inconsistencies exist regarding the effects of 
eucaloric IF in healthy individuals, preliminary results for hypocaloric IF in individuals with 
DM2 seem promising. 
 
1.6 High-Protein Diets in Weight Loss and Management of DM2 
High-Protein Diets (HPDs) are not well defined in the literature, but remain highly 
popularized as integral parts of many commercial diets. Commonly used cut-offs for high protein 
intake are 1.5-2.0g/kg of lean body mass or 30% of daily energy intake (94–97). There is 
considerable evidence of the positive effects of HPDs. Improvements in metabolic risk factors, 
and decreases in abdominal fat mass, weight, and HbA1c have been observed with the use of 
HDPs by individuals with DM2 (94,95,97). HPDs have been shown to increase the retention of 
lean mass in individuals during a hypocaloric diet while improving cardiovascular risk markers 
compared to diets with standard and/or low levels of protein (98–100). The positive effects of 
HPDs have been primarily attributed to enhanced satiety and postprandial thermogenesis, with 
both mechanisms independently contributing to an overall negative energy balance (96). Despite 
the success of HPDs in clinical trials, one criticism of HDPs remains popularized.  
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The use of HPDs in the treatment of DM2 have been said to increase the risk of kidney 
damage due to an increased rate of nitrogen excretion (30). However, a recent trial has elucidated 
that GFR is not affected in individuals with DM2 and Stage 1-3 renal disease when dietary 
protein is increased to 30% of daily caloric intake during a hypocaloric diet (101). This trial 
showed that GFR improved with weight loss during a HPD. Given these results, little to no 
safety concerns remain regarding the use of HPDs for the treatment of DM2. 
Increased protein intake in individuals with DM2 without severe renal disease is safe, 
promotes the reduction in ad lib calorie intake, improves satiety, retains lean mass, increases 
thermogenesis, and improves cardio-metabolic risk factors in DM2. Therefore, clinicians and 
dieticians should consider integrating higher protein intake into current nutrition guidelines and 
practices for individuals with DM2.  
 
1.7 Effects of Coffee and Tea Consumption on Individuals with DM2 
  A common and overlooked aspect of clinically tested IF regimens are the allowance of zero 
calorie coffee and tea intake on metabolic risk markers in DM2. Although no clinical trials have 
been done to assess the long-term effects of increasing coffee and tea intake in individuals with 
DM2, there is an abundance of observational studies on the effects of coffee and tea intake on 
DM2, and several short-term trials assessing the acute effects of coffee and tea intake on 
metabolism in healthy individuals. The highest percentiles of coffee intake have been implicated 
in an inverse relationships with the development of DM2 (102), total mortality, cardiovascular 
disease, and stroke in those with DM2 (103,104), and weight (105). Acute coffee ingestion has 
been shown to increase metabolic rate, thermogenesis and restrict ad libidum energy intake 
(106,107), and increase antioxidant capacity (108). Acute coffee ingestion also promotes the 
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secretion of Glucagon-like Peptide 1 (GLP-1) (109), a pro-insulinogenic anti-hyperglycemic 
incretin which has therapeutic implications for the treatment of DM2 by suppressing hunger and 
restricting energy intake (110), as well as in vitro evidence that it may increase beta cell mass 
(111). However, long-term randomized clinical trials on coffee and tea intake are needed in order 
to confirm the results of these short-term and observational studies.  
 
1.8 Risk of Hypoglycemia during Fasting – Evidence from Ramadan 
 Little to no information exists on the potential hypoglycemic effects of IF on individuals 
with DM2, particularly for those who are on glucose lowering medications. The study by 
Kahleova et al. did not report on the occurrence of hypoglycemia in relation to fasting duration 
or medication during IF (93). However, information on the risk of hypoglycemia during a 
prolonged fast is present in other practices that share similarities to IF. 
Ramadan is an Islamic holy month whereby religious practitioners abstain from all food 
and liquid intake from sunrise to sunset for 29-30 consecutive days. Ramadan is markedly 
different compared to IF: it restricts all fluid intake during fasting hours (112), may disturb sleep 
patterns (113), has variable length and therefore metabolic effects dependent on time of year and 
location (114), and typically involves meal intake in both the early morning and late evening. 
However, it can be used to assess the risk of hypoglycemia during prolonged fasting, as 
individuals observing Ramadan fast for 12-20 hours consecutively each day. It has been shown 
that during this time, rates of hyperglycemia requiring hospitalization decline among those with 
DM2, while rates of hypoglycemia requiring hospitalization increase – the latter due primarily 
from the use of sulfonylureas, improper insulin administration, and hypoglycemic unawareness 
(115).  
 22 
 Current recommendations for individuals with diabetes during Ramadan that are relevant 
to those with DM2 practicing IF is the use of frequent self-monitoring of glucose levels, 
immediately breaking the fast if hypoglycemic (blood glucose <3.9 mmol), not fasting while ill, 
a medical assessment and patient education by a physician before beginning a month of fasting, 
altering the timing and method of administering medications during Ramadan, and finally, not 
engaging in Ramadan if certain medications are taken (see Table 1) (116). Considerable attention 
must be paid to the type of medication and health status of the individual before engaging in 
fasting.  
 
Table 1.1 – Risk of Hypoglycemia from Diabetes Medications during Ramadan: Summary of 
results from Al-Arouj et al. (116) 
Medication Recommendation 
Metformin Metformin is generally considered safe, as the risk of 
hypoglycemia during Ramadan is relatively low.  
Sulfonylureas  The use of sulfonylureas should be individualized for each 
patient. An adequate history of prior hypoglycemic 
occurrence should be considered before Ramadan. Certain 
sulfonylureas should be considered safe. The newer 
generation of these medications (gliclazide, glimepiride) 
have a lower risk of hypoglycemia. The use of 
chlorpropamide has a high chance of causing hypoglycemia 
and should not be used during prolonged fasts.    
Glitazones Insulin sensitizers are generally considered safe during 
Ramadan and present a low risk of hypoglycemia.  
Short-Acting Insulin 
Secretagogues 
Repaglinide and Nateglinide are generally considered safe, 
so long as they are only taken before meals during 
Ramadan. 
Insulin  There is some evidence that the combination use of long 
acting insulin and short acting insulin can be used safely 
during Ramadan. However, this takes considerable attention 
on behalf of the individual and poses a greater risk of 
hypoglycemia compared to some oral agents.  
 23 
CHAPTER 2 
PURPOSE, OBJECTIVES, AND HYPOTHESIS 
 
2.1 Purpose of Project 
According to the Canadian Diabetes Association, nutritional interventions are considered 
an integral strategy for managing and preventing the complications that may arise in DM2 (29). 
With this in mind, Intermittent Fasting, a popularized nutritional intervention whereby energy 
intake is restricted for a pre-defined and extended period of time, may prove to be a beneficial 
addition to the current nutritional interventions commonly used in standard DM2 treatment. 
Individuals with DM2 have metabolic adaptations that may be of benefit during a fast, benefit 
from the creation of a spontaneous caloric deficit and increased protein, coffee and tea intake, 
and exhibit delayed diurnal insulin sensitivity. As such, IF with a high protein diet may be 
beneficial for those with DM2. If the IF method described previously proves to be an effective 
treatment for DM2, it may give those who have failed at implementing standard lifestyle 
interventions another chance at managing their diabetes. Intermittent Fasting may circumvent the 
use of costly surgeries or medications, while requiring little alteration in current exercise habits, 
food choices, and other aspects of lifestyle. 
The purpose of this clinical trial is to evaluate the short-term biochemical and behavioral 
effects of a popularized version of IF on free-living adults with DM2 given minimal education. 
 
2.2 Objectives and Aims 
Objective 1 
Observe the biochemical and clinical effects of Intermittent Fasting on individuals with Diabetes 
Mellitus 2.  
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Specific Aim 1  
Reduce fasting plasma glucose, SMBG, C-reactive protein, HOMA-IR, and waist circumference. 
Specific Aim 2 
Observe the effects on creatinine clearance and weight. 
Objective 2 
Observe the behavioral effects of Intermittent Fasting on energy intake, macronutrient intake, 
compliance and tolerability. 
Specific Aim 1 
Record hours fasted, energy intake, macronutrient composition, and coffee/tea intake. 
Specific Aim 2 
Assess the tolerability and perception of IF in participants via written questionnaires.  
Specific Aim 3 
 Assess appetite, hunger, and satiety through the use of visual analog scales. 
 
2.3 Hypothesis 
  We hypothesize that a short-term period of IF in individuals with DM2 will lead to 
improvements in glycemic control, inflammatory biomarkers, and insulin sensitivity, while 
demonstrating compliance and tolerability. 
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CHAPTER 3 
METHODS 
 
3.1 Participant Recruitment and Eligibility 
3.1.1 Power Analysis and Recruitment 
A power analysis was performed, which found that 33 participants were necessary to 
detect a 3cm change in waist circumference, a 0.75mmol change in C-reactive protein, or a 
0.75mmol change in fasting blood glucose with a power of 80% and 95% confidence. We 
recruited participants from posters placed in general practitioners’ offices in the Saskatoon 
Health Region, Royal University Hospital, and the University of Saskatchewan. Advertisements 
were also placed in classified advertisements in newspapers and Kijiji. A contact number and e-
mail address was displayed on all advertisements. Upon contact from participants, the M.Sc.(c) 
explained the study in detail over phone, confirmed that prospective participants met 
inclusion/exclusion criteria, and acquired verbal consent prior to the first meeting and receiving 
signed consent. Ten participants with DM2 were recruited for the study.  
 
3.1.2 Inclusion/Exclusion Criteria 
Individuals with a diagnosis of DM2 (confirmed by fasting glucose >7.0mmol, HbA1c > 
6.5%, or OGTT > 11.0mmol) and between the ages of 18-65 were eligible to enroll in this study. 
Certain medical conditions were excluded from enrollment, such as the presence of ischemic 
heart disease or heart failure, chronic inflammatory diseases, chronic infections, moderate to 
severe renal disease (GFR<45), uncontrolled hypertension or hypoglycemic unawareness as 
these complications may have increased the likelihood of adverse events. Participants with DM2 
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on glyburide or insulin were excluded from the study due to their increased risk of 
hypoglycemia, while Dr. Arnason and Dr. Mansell assessed others on a case-by-case basis.  
 
3.2 Study Design 
Consenting participants that met inclusion criteria engaged in a six or eight week 
withdrawal study testing the effects of intermittent fasting. The duration was dependent on the 
time of recruitment. Initially the study was advertised as a 6-week study, and after 5 participants 
were recruited the duration of the study was increased to 8 weeks to extend the period of IF. 
However, the study was changed back to its original 6-week duration in an attempt to increase 
recruitment. In total, 7 participants completed the 6-week study, and 3 participants completed the 
8-week study.  After participants met study requirements and signed consent, they were educated 
on study procedures by a M.Sc.(c) in Pharmacy. Dr. Welihinda or Dr. Arnason then educated 
participants on the risk and management of hypoglycemia during IF, and acquired a complete 
family and medical history. 
 
Figure 3.1 – Study Design 
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During the study, participants engaged in normal dietary patterns (breakfast, lunch and 
dinner) during weeks 1-2 (baseline) and 5-6 or 7-8 (follow-up) (Figure 1). For weeks 3-4 or 3-6 
(intervention) participants followed the IF meal timing pattern of daily fasts for 18-20h per day, 
followed by a 4-6h feeding periods (see Figure 1.). Ad libidum zero-calorie coffee and tea intake 
during fasting hours were permitted, and an emphasis was placed on high protein foods during 
the feeding periods for weeks 3-4/3-6. In order to educate participants on high protein food, they 
were shown images of high-protein foods and given a list of high protein foods with their 
corresponding protein content by serving size.  
 
3.3 Data Collection and Endpoints 
3.3.1 Self-Reporting: Hours Fasted, Self-Monitored Blood Glucose, Remote Food 
Photography, and Visual Analog Scales 
Throughout all study phases participants reported SMBG with the use of a glucometer 
and logbook that was provided to them by study staff. Participants were instructed to measure 
blood glucose with their glucometers three times per day: morning (fasted), afternoon (random) 
and evening (random). In the same logbook, they also kept a diary of total consecutive hours 
fasted each day. In each of the three time periods (baseline, intervention, follow-up) participants 
completed a random 3-day food diary using the Remote Food Photography Method (RFPM) 
(117), in tandem with a visual analog scale for satiety and hunger ratings (54).  During these 
days, participants received customized text message prompts by study staff to ensure compliance 
with RFPM, in addition to text messages with numbered visual analog scales so they may rate 
perceived hunger and satiety before and after meals. Participants responded to all text prompts to 
 28 
confirm that they had adhered to RFPM, as well as sent images of their food (before and after 
consumption to capture food waste) and the scores of their visual analog scales. 
 
3.3.2 Biochemical and Anthropometric Measurements 
Participants underwent fasted blood draws at the Royal University Hospital blood draw 
clinic on the first and last days of the intervention phase, as well as on the last day of the follow-
up phase to determine the acute and sustained effects of IF on glycemic control and insulin 
resistance (FPG, Fasting Insulin, HOMA-IR), kidney function (Creatinine, Creatinine 
Clearance), and inflammation (CRP). On each of these days, participants also underwent 
anthropometric measurements (Height, Weight, BMI, Waist Circumference), as well as the 
YPAS to control for variations in physical activity. Additional measures, which are not the focus 
of this thesis, were also collected for ferritin, low-density lipoprotein (LDL), high-density 
lipoprotein (HDL), total cholesterol (TC), and triglycerides (TG).   
 
3.4 Statistical Analysis 
All statistical procedures were performed on SPSS v. 22 and STATA v. 13. Data 
preparation was done using Excel 2011 and STATA v. 13. Significance was set at alpha = 0.05 
(95% confidence) for all tests. Trends were identified through visual inspection. 
 
3.4.1 Repeated Measures ANOVA  
Ten individuals (9 female, 1 male) completed three blood draws, and the intervention and 
follow-up periods. Nine individuals (8 female, 1 male) completed the lead-in phase and all 
SMBG logs, 1 of which submitted incomplete logs of daily hours fasted (HF) for the lead-in and 
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follow-up phases. Missing means from incomplete logs of SMBG and HF or missing values 
from blood draws or clinical measurements required for Repeated Measures ANOVA were 
imputed with the following formulas: 
Baseline = x1, Intervention = x2, Follow-up = x3 
x1 = -(μΔx1-2 * x2) + x2 
x2 = (μΔx1-2 * x1) + x1 
x3 = (μΔx2-3 * x2) + x2 
Data that did not pass the sphericity assumption were interpreted using the Greenhouse-Geisser 
correction, and data that showed large violations of normality were interpreted with Friedman’s 
test. 
 
3.4.2 Self-Monitored Blood Glucose Data Preparation 
During construction of the regression models for SMBG, imputation was not performed. 
The participant who did not complete the lead-in phase was excluded from the analysis; only 
participants who completed full SMBG logs for every study phase were included. To account for 
variance in the length of baseline, intervention, and follow-up phases, participants’ logs were 
equalized at 42 days (14 days for each phase). The equalization procedure was done in a 
stepwise manner until each study phase contained 14 days:  
1) If phase x = 14 days no adjustments were made 
2) If phase x > 14 days, days with no data were removed. 
3) If phase x > 14 days after Step 2: Days with incomplete data were removed. In the event 
of a tie (i.e. two days had equal amounts of missing data), the day closest to the beginning 
or end of a phase was removed to foster independence between experimental conditions. 
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4) If phase x > 14 days after Step 3: Days at the beginning or end of a phase were removed 
to foster independence between study phases. 
5) If phase x < 14 days, days were added to the end of that phase and left blank. 
Three individuals completed an intervention phase with an average duration of 26 days. 
Because of the significantly larger sample size, the equalization procedure above could not be 
fully applied without possibly compromising the validity of the regression model. In order to 
account for any possible variance that occurred due to a result of the prolonged intervention, 3 
data sets for morning, afternoon, and evening SMBG  (M, A, E) were constructed using the 
beginning (B), middle (M), and last (E) 14 days of the intervention phase as input for the group 
means used in the regression models. Afterwards, the equalization procedure was implemented 
until each phase consisted of 14 days. 
 
3.4.3 Self-Monitored Blood Glucose Regression Models 
After data preparation, the group means and standard deviations of days 1 through 42 
were calculated individually for three daily measurements: fasted Morning (M), random 
Afternoon (A), and random Evening (E) SMBG measurements. Additionally, three group means 
and standard deviations were created for each data set generated: Beginning (B), Middle (M), 
and End (E). This generated 9 regression models (MB, MM, ME; AB, AM, AE; EB, EM, EE) 
for both the means and standard deviations (μMB, σMB; μMM, σMM; μME, σME; μAB, σAB: 
μAM σAM; μAE, σAE; μEB, σEB; μEM, σEM; μEE, σEE) – 18 models in total. Inflection 
points of quadratic equations were calculated using the formula [f 
1 
(y) of C + Ax + Bx
2
 = 0] 
rounded down to the nearest full integer. Regressing group means and standard deviations 
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individually led to the creation of models that could be used to interpret the effect of IF on mean 
group SMBG, as well as the effect of IF on the variability of group SMBG.  
 
3.4.4 Two-Sample Kolmogorov-Smirnov and Ordinal Logistic Regression Tests 
After regression with SMBG data, the two-sample Kolmogorov-Smirnov (KS) test and 
Ordinal Logistic Regression (OLR) were used to further explore the effects of the experimental 
intervention as well as the direct impact of fasting on SMBG. Cut-offs for OLR were created 
using standard guidelines for diabetic fasting and random blood glucose (7.0mmol/L and 
11.1mmol/L respectively) (6), with an additional arbitrary stratification of hyperglycemia 
reflecting the midpoint (9.05mmol/L) for morning, afternoon, and evening SMBG values (Table 
2). No category was created to represent hypoglycemic events, as none were recorded throughout 
the duration of the study. For both the KS test and OLR, full non-equalized SMBG data sets 
were used.  
 
Table 3.1 – Cut-offs for Ordinal Logistic Regression 
Cut-off Definition 
1 <= 7.0mmol/L (Normal Fasting Glucose) 
2 7.0mmol/L - 9.05mmol/L (Fasting Hyperglycemia/Random normoglycemia) 
3 9.05mmol/L - 11.1mmol/L (Fasting Hyperglycemia/Random normoglycemia) 
4 => 11.1mmol/L (Random Hyperglycemia) 
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 The KS test compared the individual distributions of baseline, intervention, and follow-
up phases separately for morning, afternoon, and evening SMBG. Two variables were created for 
OLR: Hours Fasted Difference (HFD) and Hours Fasted Difference by Percent (HFP): 
HFD = Hours Fasted – Average Hours Fasted during baseline 
HFP = (HFD/Average Hours Fasted during baseline)*100 
OLR was used to elucidate the effect of HFD and HFP on morning, afternoon, and evening 
SMBG between phases that were shown to have different SMBG distributions with the KS test. 
 
3.5 Ethical Considerations 
 Privacy and confidentiality are paramount when conducting any human biomedical 
research. Any paper files are stored in a locked filing cabinet in Dr. Arnason’s secure clinical 
office in Royal University Hospital. All digital data was completely de-identified, and a key to 
the de-identified data is kept on paper and stored alongside other paper files in Dr. Arnason’s 
office. Patient contact information was stored on the personal password protected and encrypted 
mobile phone of the M.Sc. (c) under pseudonyms, and all text messages and images were 
promptly deleted after being sent and/or recorded. Participants were instructed not to include 
themselves or any identifiers in images or messages sent over text message and e-mail. 
 All research data will be stored for a period of five years. Paper data is stored in the 
locked filing cabinet within Dr. Arnason’s office, and all digital data will be stored on a USB 
drive locked within Dr. Arnason’s office. 
 Ethics were obtained in March 2014 from the Research Ethics Office at the University of 
Saskatchewan. 
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CHAPTER 4 
RESULTS 
 
4.1 Baseline Characteristics of Participants 
 10 participants completed the study, with 7 individuals completing the 6-week study and 
3 individuals completing the 8-week study. The mean age of participants was 53.8 years old 
(Table 4.1). All participants were on metformin, and most were on other non-diabetic 
medications. Herbals and supplement use was present in 6 patients at baseline. Only two 
participants were on other diabetic medications in addition to metformin (liraglutide and a 
sulfonylurea), and only one participant was an occasional/active smoker (Table 4.2). There were 
significant variations between participants at baseline in several key measures such as weight, 
BMI, ferritin, triglycerides, HOMA-IR, CRP, and fasting insulin (Table 4.3). At baseline, 
participants had confirmed DM2, and on average were obese (BMI > 30.0kg/m
2
), with waist 
circumferences above cut-off values (>88cm in women, >102cm in men).    
   
Table 4.1 – Baseline Characteristics of 10 Participants 
Measure Mean ± Standard Deviation 
Age  53.8 ± 9.11 years old 
Weight  100.6 ± 21.75 kg 
BMI 36.9 ± 8.29 kg/m
2
 
Waist Circumference 109.6 ± 11.1 cm 
Daily Hours Fasted 11.6 ± 1.9 hours/day 
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Table 4.2 – Baseline Smoking, Medication, and Supplement use 
 Currently using 
Metformin 10 (10) 
Sulfonylureas  1 (10) 
Other diabetic medications 1 (10) 
Other non-diabetic 
medications 
8 (10) 
Herbals and Supplements 6 (10) 
Active Smokers 1 (10) 
 
4.2 Biochemical and Anthropometric Changes 
Significant differences from baseline to intervention were noted in weight (-1.395kg, p = 
0.009) and BMI (-0.517, p = 0.013), with non-significant differences in WC (-1.75cm, p = 
0.083). CRP lowered from baseline to intervention in 8 of 10 participants, however, a large 
magnitude increase in CRP in a single participant during IF rendered the results non-significant. 
From baseline to follow-up there were non-significant decreases in weight (-1.120kg, p = 0.078), 
and BMI (-0.417kg/m
2
, p = 0.083), while all other parameters had a tendency to regress to 
baseline values during the follow-up period. No significant differences were observed in any 
other parameters between any time points (Table 4.4).  
 Table 4.3 - Descriptive Statistics and Assumptions for Biochemical and Anthropometric Parameters 
Outcome Measure Baseline Intervention Follow-up 
Sphericity Residual 
Normality 
Ferritin (μg/L) Mean 118.30 123.70 118.30 No No 
 (RR: 20-120) Std. Dev 98.48 96.57 92.66   
T/HDL Mean 3.52 3.44 3.57 Yes Yes 
 (RR: < 3.5) Std. Dev 0.73 0.97 1.08   
LDL (mmol/L) Mean 2.51 2.38 2.43 Yes No 
 (RR: 2.2-3.4) Std. Dev 0.76 0.95 0.82   
HDL (mmol/L) Mean 1.31 1.32 1.31 Yes Yes 
 (RR: 0.9-2.4) Std. Dev 0.20 0.27 0.30   
Triglycerides (mmol/L) Mean 1.57 1.52 1.72 Yes Yes 
 (RR: 0.6-2.3) Std. Dev 0.91 0.74 0.90   
TC (mmol/L) Mean 4.53 4.39 4.52 Yes Yes 
 (RR: 4.2-5.2) Std. Dev 0.77 0.99 1.05   
C-Reactive Protein (mg/L) Mean 4.31 3.97 4.06 Yes Yes 
 (RR: < 1.0) Std. Dev 3.80 3.71 3.47   
Fasting Insulin (pmol/L) Mean 129.29 116.57 116.06 Yes Yes 
 (RR: 43.0-194.0) Std. Dev 62.21 44.38 57.43   
Glucose (mmol/L) Mean 7.45 7.61 7.93 Yes Yes 
 (RR: 3.6-6.0) Std. Dev 1.52 1.02 1.58   
HOMA-IR Mean 6.91 6.45 6.56 Yes Yes 
 N/A Std. Dev 3.00 2.39 3.04   
Creatinine (μmol/L) Mean 63.80 63.40 62.40 Yes Yes 
 (RR: 45-90) Std. Dev 5.90 6.48 7.46   
CCr (mL/min) Mean 149.01 147.90 151.50 Yes Yes 
 (RR: > 90) Std. Dev 46.98 51.35 53.32   
Weight (kg) Mean 100.6 99.21 99.48 Yes Yes 
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   Std. Dev 21.75 21.33 21.48   
BMI (kg/m^2) Mean 36.90 36.38 36.48 Yes Yes 
 (RR: < 25.0) Std. Dev 8.29 8.10 8.14   
Systolic BP (mmHg) Mean 130.00 127.00 128.50 Yes Yes 
 (RR: 90-130) Std. Dev 17.80 21.39 14.28   
Diastolic BP (mmHg) Mean 80.50 79.78 81.70 Yes Yes 
 (RR: 60-90) Std. Dev 13.20 15.66 12.25   
Waist Circumference (cm) Mean 109.55 107.80 107.50 No Yes 
 (RR: <88cm, <102cm) Std. Dev 11.08 11.09 10.86   
Daily Hours Fasted Mean 11.61 16.82 11.52 Yes Yes 
 N/A Std. Dev 1.89 1.18 2.01   
Days In Phase Mean 15.10 18.20 15.8 N/A N/A 
 N/A Std. Dev 1.97 5.69 4.10   
μMorning SMBG (mmol/L) Mean 8.16 7.73 8.09 No Yes 
 N/A Std. Dev 1.28 1.823 1.39   
μAfternoon SMBG (mmol/L) Mean 7.47 7.1659 7.02 Yes Yes 
 N/A Std. Dev 0.99 1.16 0.90   
μEvening SMBG (mmol/L) Mean 8.71 8.58 8.76 Yes Yes 
 N/A Std. Dev 1.87 1.89 1.68   
T/HDL = Total cholesterol:HDL ratio, HDL = High-Density Lipoprotein, LDL = Low-Density Lipoprotein, TC = Total 
Cholesterol, HOMA-IR = Homeostasis Model Assessment, CCr = Creatinine Clearance, BMI = Body Mass Index, BP = Blood 
Pressure, μ = average, SMBG = Self-Monitored Blood Glucose, RR = Reference Range 
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Table 4.4 – Percent Change Between Study Phases for Biochemical and Anthropometric 
Parameters  
Outcome (Δ= % change) Measure 
Baseline to 
Intervention 
Intervention 
to Follow-up 
Baseline to 
Follow-up 
ΔFerritin  Mean +9.85% -3.06% +5.99% 
  Std. Dev 19.60 8.70 19.88 
ΔT/HDL Mean -3.03% +5.08% +1.16% 
  Std. Dev 12.12 17.20 16.49 
ΔLDL Mean -6.34% +5.95% -3.10% 
  Std. Dev 18.05 17.90 12.54 
ΔHDL Mean +0.85% +0.37% +0.13% 
  Std. Dev 10.18 19.49 14.89 
ΔTriglycerides  Mean +5.31% +19.58% 17.96% 
  Std. Dev 37.75 33.25 33.93 
ΔTC Mean -3.56% +3.36% -0.90% 
  Std. Dev 10.16 10.46 9.38 
ΔC-Reactive Protein  Mean -5.75% +47.18% +23.95% 
  Std. Dev 37.49 155.07 119.96 
ΔInsulin  Mean -3.38% +0.095% -7.64% 
  Std. Dev 35.05 31.43 36.49 
ΔGlucose  Mean +3.89% +3.69% +7.10% 
  Std. Dev 11.43 12.60 13.24 
ΔHOMA-IR Mean +1.70% +3.96% -0.10% 
  Std. Dev 42.88 35.01 42.72 
ΔCreatinine  Mean -0.50% -1.28% -2.19% 
  Std. Dev 7.25 9.56 6.81 
ΔCCr Mean -0.94% +1.97% +0.67% 
  Std. Dev 8.11 9.52 9.20 
ΔWeight  Mean -1.36% +0.27% -1.10% 
  Std. Dev 1.02 1.12 1.31 
ΔBMI  Mean -1.35% +0.26% -1.10% 
  Std. Dev 1.02 1.12 1.31 
ΔSystolic BP  Mean -2.95% +0.62% -2.31% 
  Std. Dev 6.24 7.30 6.40 
ΔDiastolic BP  Mean -2.31% +2.58% +0.98% 
  Std. Dev 14.24 5.90 12.08 
ΔWaist Circumference  Mean -1.60% -0.26% 1.85% 
  Std. Dev 1.98 1.78 3.13 
ΔDaily Hours Fasted Mean +30.74% -46.19% -1.72% 
  Std. Dev 11.58 26.88 13.65 
ΔμMorning SMBG Mean -8.54% +5.07% -1.35% 
  Std. Dev 22.10 9.67 10.76 
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ΔμAfternoon SMBG Mean -5.05% -1.76% -6.32% 
  Std. Dev 10.18 7.40 8.34 
ΔμEvening SMBG Mean -2.02% +1.82% +1.17 
  Std. Dev 11.16 10.82 6.86 
T/HDL = Total cholesterol:HDL ratio, HDL = High-Density Lipoprotein, LDL = Low-
Density Lipoprotein, TC = Total Cholesterol, HOMA-IR = Homeostasis Model 
Assessment, CCr = Creatinine Clearance, BMI = Body Mass Index, BP = Blood Pressure, 
μ = average, SMBG = Self-Monitored Blood Glucose 
 
 
4.3 Self-Monitored Blood Glucose 
 Nine participants self-reported fasted morning, random afternoon, and random 
evening SMBG with the use of a provided glucometer and logbook throughout all study 
phases. Among these participants, adherence to SMBG reporting was highest for fasted 
morning readings with only 7 missing data points, followed by random afternoon and 
evening with 48 and 53 data points missing among all participants, respectively. 
Throughout the study duration, participants recorded a total of 409 morning fasted, 368 
random afternoon, and 363 random evening SMBG readings. 
   
4.3.1 Regression Models of Self-Monitored Blood Glucose  
SMBG Regression Models were built using the means from 9 participants who 
completed full SMBG logs. All 18 data sets and their residuals passed the normality 
assumptions necessary for simple linear regression using Shapiro-Wilk (Table 4.5) and 
visual inspection of histograms and Q-Q plots with the exception of the residuals from 
the linear models for μEB and σME (p < 0.05). All models were clear of autocorrelation, 
which was confirmed via analysis of residual distributions and ACF graphs.  
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Table 4.5 – Regression Assumptions for Self-Monitored Blood Glucose  
 
Data Residuals 
Statistic df P-value Statistic df P-Value 
μMB-Q .958 42 .130 .972 42 .396 
σMB-Q .978 42 .593 .972 42 .393 
μAB-L .977 42 .558 .980 42 .642 
σAB-L .981 42 .713 .973 42 .407 
μEB-L .948 42 .054 .947 42 0.49 
σEB-L .986 42 .876 .981 42 .711 
μMM-Q .981 42 .717 .989 42 .958 
σMM-Q .964 42 .206 .964 42 .203 
μAM-L .971 42 .345 .967 42 .261 
σAM-L .971 42 .354 .966 42 .234 
μEM-L .977 42 .531 .973 42 .426 
σEM-L .983 42 .770 .989 42 .947 
μME-Q .977 42 .538 .983 42 .203 
σME-Q .968 42 .280 .941 42 .032 
μAE-L .950 42 .066 .954 42 .087 
σAE-L .975 42 .473 .969 42 .295 
μEE-L .988 42 .929 .988 42 .935 
σEE-L .968 42 .288 .983 42 .774 
Q = Quadratic model, L = Linear model, μ = average, σ = standard deviation, MB = 
morning with beginning 14 days data, MM = morning with middle 14 days glucose 
data, ME = morning with end 14 days glucose data, AB = afternoon with beginning 
14 days glucose data, AM = afternoon with middle 14 days glucose data, AE = 
afternoon with end 14 days glucose data, EB = evening with beginning 14 days 
glucose data, EM = evening with middle 14 days glucose data, EE = evening with 
last14 days glucose data, df = degrees of freedom 
 
Table 4.6 contains the full set of quadratic and linear models of SMBG generated 
with their accompanying statistical information. All quadratic models for μMorning 
SMBG were significant (p < 0.0005) and showed moderate to weak R
2
 values with 
distinct nadirs during the IF phase, indicating a decrease in average fasted morning 
SMBG during the IF intervention. All quadratic models for σMorning SMBG were 
significant (p < 0.0005) and showed moderate R
2
 values with distinct peaks in the IF 
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phase, indicating an increase in SMBG variability during the IF intervention. All models 
for μAfternoon SMBG showed trends of decreasing SMBG levels throughout the entire 
study period (p = 0.108, 0.133, 0.158), but R
2
 values indicated the models were weak. 
Many models for μAfternoon became weaker once non-significant coefficients were 
dropped (data not shown). σAfternoon SMBG showed weak accordance with quadratic 
models, giving some indication that the variability of afternoon SMBG may have 
increased marginally during the IF phase. Models for μEvening SMBG had no 
accordance with any linear or non-linear models (all p > 0.1, data not shown). However, 
σEvening SMBG were significant (all p < 0.05), indicating that variability decreased 
linearly over the entire study period, but these models were relatively weak (R
2 
< 0.15).  
Inflection points, which are representative of either the peak or nadir of the quadratic 
models, were calculated to lie within or immediately after the intervention phase (Days 
14-28). In summation, mean morning SMBG values decreased during IF and regressed 
towards baseline during follow-up (Figure 4.1), while morning SMBG variability 
increased as a result of IF (Figure 4.2). Mean afternoon SMBG, mean evening SMBG, 
and afternoon SMBG variability did not significantly change over the study period, but 
evening SMBG variability decreased linearly throughout the entire study’s duration 
(Figure 4.3). These models suggest decreased glycemic variability in the evening, and 
more variable but lower mean fasted morning glycemia.  
 Table 4.6 - Self-Monitored Blood Glucose Regression Models 
 
Measure Model R R
2 
F-stat. P-value Coefficients P-values IFP 
μMB Quad 0.664 0.441 15.376 < 0.0005 8.728 - 0.072Day + 0.002Day2 All < 0.0005 18 
σMB Quad 0.699 0.488 18.617 < 0.0005 0.787 + 0.085Day - 0.002Day2 All < 0.0005 21 
μMM Quad 0.593 0.352 10.581 < 0.0005 8.714 - 0.066Day + 0.001Day2 All < 0.0005 33 
σMM Quad 0.706 0.498 19.332 < 0.0005 0.752 + 0.097Day – 0.002Day2 All < 0.0005 24 
μME Quad 0.537 0.288 7.903 0.001 8.67 – 0.056Day + 0.001Day2 All < 0.0005 28 
σME Quad 0.692 0.479 17.942 < 0.0005 0.815 + 0.088Day – 0.002Day2 All < 0.0005 22 
μAB Linear 0.251 0.063 2.698 0.108 7.642 – 0.01Day < 0.0005, 0.108  
σAB Linear 
Quad 
0.286 
0.414 
0.082 
0.171 
3.552 
4.022 
0.067 
0.026 
1.860 – 0.013Day 
1.475 + 0.040Day – 0.001Day2 
< 0.0005, 0.067 
< 0.0005, 0.139, 0.047 
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μAM Linear 0.236 0.056 2.354 0.133 7.668 – 0.01Day  < 0.0005, 0.133  
σAM Linear 
Quad 
0.259 
0.395 
0.067 
0.156 
2.865 
3.604 
0.098 
0.037 
1.876 – 0.013Day 
5.297 + 0.045Day – 0.001Day2 
< 0.0005, 0.098 
< 0.0005, 0.049, 0.0132 
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μAE Linear 0.222 0.049 2.075 0.158 7.658 – 0.01Day < 0.0005, 0.158  
σAE Linear 
Quad 
0.293 
0.424 
0.086
0.179 
3.756 
4.262 
0.06 
0.021 
1.897 – 0.014Day 
1.478 + 0.043Day – 0.001Day2 
< 0.0005, 0.06 
< 0.0005, 0.129, 0.041 
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μEB None        
σEB Linear 0.319 0.102 4.525 0.040 2.663 – 0.016Day < 0.0005, 0.04  
μEM None        
σEM Linear 0.333 0.111 5.001 0.031 2.781 – 0.018Day < 0.0005, 0.031  
μEE None        
σEE Linear 0.329 0.108 4.850 0.033 2.687 – 0.017Day < 0.0005, 0.033  
Quad = Quadratic model, Linear = Linear model, μ = average, σ = standard deviation, MB = morning with beginning 14 days data, 
MM = morning with middle 14 days glucose data, ME = morning with end 14 days glucose data, AB = afternoon with beginning 14 
days glucose data, AM = afternoon with middle 14 days glucose data, AE = afternoon with end 14 days glucose data, EB = evening 
with beginning 14 days glucose data, EM = evening with last 14 days glucose data, EE = evening with middle 14 days glucose data, 
IFP = Inflection Points 
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Figure 4.1 – Mean Morning Fasted Self-Monitored Blood Glucose 
 
Figure 4.2: Morning Fasted Self-Monitored Blood Glucose Variability 
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Figure 4.3: Evening Random Self-Monitored Blood Glucose Variability 
 
 
4.3.2. Self-Monitored Blood Glucose Distributions  
The Kolmogorov-Smirnov (KS) test was used to analyze data from all 9 individuals who 
had completed their full SMBG logs. Unlike the regression models, the KS test used the non-
equalized data sets, as non-equalized and equalized data sets showed good agreement and non-
equalized data sets made full use of all the collected data.  
Results of the KS test indicated that the distribution of morning SMBG was different 
between baseline and intervention phases (p = 0.002) and between intervention and follow-up 
phases (p = 0.003), but there was no difference detected between baseline and follow-up phases 
(p = 0.55). There was a significant difference between intervention and follow-up phases for 
evening SMBG distributions (p = 0.044), but not between any other phases (all p > 0.1). No 
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significantly different distributions were detected between any phases for afternoon SMBG (all p 
> 0.1).  
 In order to investigate the nature of the difference in distributions seen in the KS test, raw 
counts and percentages for categories used in OLR were tabulated for each phase. For morning 
SMBG, there was a 20.3% percent increase in the occurrence of SMBG < 7.0 mmol/L, a 6.3% 
increase in the occurrence of SMBG => 11.1 mmol/L, and a 26.6% decrease in the occurrence of 
SMBG 7.0-11.1 mmol/L from baseline to intervention phase (Table 4.7). This confirmed that the 
increase in variability seen in morning SMBG regression models (section 4.3.1) was due 
primarily to an increase in the frequency of normoglycemia and a decrease in the frequency of 
hyperglycemia (7.0 - 11.1mmol/L) during the intervention phase. This also confirms that the 
decrease in mean fasted morning SMBG seen in the regression models (section 4.3.1) was valid, 
and the increase in SMBG variability was due primarily to an increase in normoglycemia 
(SMBG < 7.0mmol/L).  
For evening SMBG, there was a 17.7% increase in the frequency of SMBG 7.0 – 11.1 
mmol/L, a 14.7% decrease in SMBG < 7.0 mmol/L, and a 2.9% decrease in SMBG => 11.1 
mmol/L from intervention to follow-up (Table 4.8). Even though no significant changes in mean 
evening SMBG were found in regression models (section 4.3.1), this suggests that the decrease 
in evening SMBG variability was likely due to an overall worsening of glycemic control during 
the follow-up period. However, since mean evening SMBG regression models in Section 4.3.1 
found no significant change in mean evening SMBG and the KS test found no difference 
between the distributions of baseline and follow-up evening SMBG, we cannot make any 
conclusive statements on IF’s impact on evening glycemic control. 
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Table 4.7 – Morning Self-Monitored Blood Glucose by Phase 
SMBG (mmol/L) Baseline Intervention Follow-up 
< 7.0 17 (13.8%) 57 (34.1%) 18 (15.1%) 
7.0 - 9.05 64 (52.0%) 68 (40.7%) 59 (49.6%) 
9.05 - 11.1 41 (33.3%) 30 (18.0%) 39 (32.8%) 
=> 11.1 1 (0.8%) 12 (7.1%) 3 (2.5%) 
Total 123 167 119 
 
Table 4.8 – Evening Self-Monitored Blood Glucose by Phase 
SMBG (mmol/L) Baseline Intervention Follow-up 
< 7.0 27 (24.5%) 42 (27.6%) 13 (12.9%) 
7.0 - 9.05 31 (28.1%) 50 (32.9%) 42 (41.6%) 
9.05 - 11.1 30 (27.3%) 30 (19.7%) 29 (28.7%) 
=> 11.1 22 (20.0%) 30 (19.7%) 17 (16.8%) 
Total 110 152 101 
 
 
4.3.3 Relationship between Hours Fasted and Self-Monitored Blood Glucose 
Ordinal Logistic Regression (OLR) was performed using data from the 8 individuals who 
had completed their full SMBG logs and daily hours fasted logs. Similar to the KS test, OLR 
models used the non-equalized data sets for the reasons mentioned in Section 4.3.2.  In order to 
explore the relationship between the increase in hours fasted and SMBG, Hours Fasted 
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Difference (HFD) and Hours Fasted Percent (HFP) were calculated for baseline and intervention 
phases only.  
HFD and HFP OLR models showed a significant association between HFD and HFP with 
morning SMBG (Chi-Square Likelihood Ratio = 8.36, p = 0.004 and Chi-Square Likelihood 
Ratio = 9.37, p = 0.002, respectively) but not for afternoon or evening SMBG (all p > 0.1). OLR 
models demonstrated that with increasing HFD and HFP, there was a significant increase in the 
probability of morning SMBG < 7.0 mmol/L and a significant decrease in the probability of 
morning SMBG > 9.05 mmol/L (Figure 4.4. and 4.5). The largest effects were observed for 
SMBG < 7.0 mmol/L and SMBG 9.05 – 11.1 mmol/L, which were inversely related. 
 
Figure 4.4 – Morning Self-Monitored Blood Glucose as a function of Hours Fasted Difference 
(HFD) 
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Figure 4.5 – Morning Self-Monitored Blood Glucose as a function of Hours Fasted Percent 
Difference (HFP) 
 
 
The follow-up phase was excluded from the results above because any after-effects from 
IF on SMBG (either positive or negative) may have distorted the relationship between hours 
fasted and SMBG. Exploratory analyses were run with data from follow-up phases included, 
which strengthened the relationships observed above (data not shown).    
Ordinal Logistic Regression of HFD and HFP OLR previous SMBG regression findings 
that mean morning SMBG levels decreased as a result of the IF intervention, and that 
improvements in morning SMBG were primarily a function of extended daily fasting durations 
relative to average baseline fasting duration. As such, the magnitude of the IF intervention was 
strongly correlated to improvements in SMBG.  
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4.4 Diet Composition, Physical Activity, Hunger and Satiety 
 There was a significant increase in self-reported daily hours fasted among all participants 
(+5.22 hours, p < 0.0005), but most participants did not regularly meet the study 
recommendations of 18-20h fasts each day (mean 16.82 ± 1.18).  Five participants partook in the 
Remote Food Photography Method (RFPM) and Yale Physical Activity Survey (YPAS). Food 
photography data was lost (due to an unknown cause) for one participant during phase 3 – as 
such, that participant was omitted from any analysis using data from phase 3. Although no 
statistically significant differences were detected in energy or macronutrient intake between any 
phases, this was likely due to the small sample size (Table 4.9). Visual inspection of the data 
demonstrated discernable trends in lower energy (-298.63 kcal/day), carbohydrate (- 47.87 
g/day), and fat (-23.2 g/day) intake during the intervention phase when compared to baseline. 
During the follow-up phase, energy intake decreased further from baseline (-498.64 kcal/day), 
and carbohydrate and fat intake remained suppressed compared to baseline (-42.04 g/day and -
30.33 g/day, respectively). However, this may have been due to loss of data from one participant 
who had the highest calorie intake among the group in baseline and intervention phases. Protein 
intake did not change throughout the study, but did increase as a percentage of total energy 
intake during the intervention phase. Physical activity, as measured by the YPAS energy 
expenditure adjustment and activity index, increased during the intervention phase (+1856.3 
kcal/week, +7.8 activity index units) and subsequently decreased in the follow-up phase, but 
there was no agreement between energy expenditure and activity index  (-2450.0 kcal/week, +3.4 
activity index units). 
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Table 4.9 – Calculated Energy and Macronutrient Intakes by Phase (5 participants) 
  Baseline  Intervention Follow-up 
Energy Intake (kcal/day) Mean 1904.3 1605.7 1510.5* 
 Std. Dev 404.1 375.5 755.4* 
Protein Intake (g/day) Mean 94.2 93.2 79.4* 
 Std. Dev 26.6 26.1 30.7* 
Carbohydrate Intake (g/day) Mean 190.6 142.7 164.2* 
 Std. Dev 58.5 62.1 93.9* 
Fat Intake (g/day) Mean 86.9 63.6 60.9* 
 Std. Dev 16.6 25.2 35.5* 
Physical Activity (kcal/week) Mean 4922.3 6778.56 4329.0 
 Std. Dev 3774.4 4329.5 3440.8 
Physical Activity (units) Mean 38.4 46.2 50.0 
 Std. Dev 18.3 14.0 27.2 
Daily Hours Fasted Mean 11.61 16.82 11.52 
  Std. Dev 1.89 1.18 2.01 
*Data from 4 Participants 
 
 Visual Analog Scales for hunger and satiety were not reported due to insufficient 
reporting by study participants. There were large gaps in the data, with several participants 
reporting hunger and satiety for less than 20% of meals recorded via food photography.  
 
4.5 Intermittent Fasting Questionnaire 
Ten participants completed their questionnaires on the IF regimen. Two participants 
remarked increased energy levels during the day. Three individuals commented on improved 
health during the intervention (related to SMBG). One participant expressed being unmotivated 
to engage in evening exercise due to hunger concerns. Three participants reported nausea with 
IF, but with a re-adjustment of medication timing nausea was no longer present in two of the 
participants. Six participants said they would continue with the IF regimen after the completion 
of the study, in a full or modified capacity (i.e. every other day or reduce fasting hours). Three 
participants said they would discontinue fasting entirely once the study was completed. The most 
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consistent complaint in the study was related to not being able to meet protein intake 
recommendations. Only two individuals remarked that their social life was negatively impacted 
by the intervention, while two other individuals commented that fasting was difficult when 
others were snacking or eating. Most individuals reported no effect on social life, and only one 
individual reported a lack of support from family and friends. Two individuals commented that 
they enjoyed not having to prepare breakfast/lunch. Four individuals said they would recommend 
IF to others, while five abstained from commenting. One individual left brief comments 
indicating that IF was tolerable, but gave no further information on any of the questions. 
 
4.6 Individual Results 
 Individual results for each participant can be found in Appendix A-J. Individual results 
were reported in order to emphasize the variability of biochemical responses observed across 
participants. 8/10 participants lost >0.5kg as a result of IF and 5/10 participants continued to lose 
weight during the follow-up phase. 3/10 participants regained the equivalent of the weight lost 
during the follow-up phase. 7/10 participants saw a decrease in waist circumference as a result of 
IF, with 4/7 losing >3cm. 5/10 participants decreased waist circumference during the follow-up 
phase as well, and 3/10 participants had a higher WC after follow-up when compared to baseline. 
4/9 participants had statistically significant decreases in morning SMBG as a result of IF, with 
3/4 showing concavity, and one participant showing a constant linear decrease throughout the 
study. 3/9 participants had statistically significant increases in morning SMBG during IF, with 
two exhibiting convexity and the 3
rd
 participant showing a constant linear increase. The 
remaining participants showed no significant changes in SMBG, however, one participant did 
show visual signs of decreases in morning SMBG. 2/9 participants showed decreases in 
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afternoon SMBG as a result of IF (one concave, one linear). One participant showed a linear 
increase in afternoon SMBG over the entire study duration. 3/9 participants showed significant 
changes in evening SMBG, one showing a concave decrease, one a convex increase, and a third 
a linear increase of SMBG throughout the study period. It is incredibly important to highlight 
individual results, as not a single participant in the study closely mimicked mean changes across 
all biochemical parameters. It is worth noting that individual results were variable, and that there 
was often little correlation between changes in SMBG, fasting hours, triglycerides, and insulin 
sensitivity (Table 4.10). 
 
Table 4.10 – Individual Changes in Fasting Hours, Triglycerides and Glycemic Control, 
Baseline to Intervention  
Participant 
Fasting 
Hours 
(%) 
Triglyceride
s (%) 
HOMA-
IR (%) 
Morning 
SMBG 
Afternoon 
SMBG 
Evening 
SMBG 
1 N/A 49.44 65.26 N/A N/A N/A 
2 21.39 12.68 66.31 Decrease Decrease None 
3 48.55 -3.03 -47.57 Decrease None None 
4 20.02 -21.88 9.28 Increase Decrease None 
5 N/A -1.69 -38.62 None None None 
6 28.93 -14.12 -28.94 Increase None Increase 
7 41.67 85.06 -6.71 Decrease None Decrease 
8 12.23 3.85 -11.99 Increase Increase Increase 
9 27.78 -50.14 43.76 None None None 
10 45.37 -7.09 -33.76 Decrease None None 
 
One participant had remarkably poor and consistent results. The participant in question 
was the only participant with a diagnosis of hypothyroidism upon initiation of the study, and was 
the only patient to show negative outcomes across all measured parameters, despite decreases in 
weight (which was all regained in follow-up). During IF, this participant had increases in LDL 
(+4.3%), TC (+1.9%), TG (+3.8%), CRP (+92.3%), waist circumference (+1.0%), morning 
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SMBG, afternoon SMBG, and evening SMBG, with decreases in HDL (-7.3%) and small 
irregular decrease in HOMA-IR (-12.0%). This participant also rated IF very poorly on her 
questionnaire and frequently complained of nausea and lack of appetite. It has been found in 
previous studies that fasting can reduce triiodothyronine and increase reverse triiodothyronine 
concentrations in healthy subjects (118), and reduce triiodothyronine receptor capacity in fasting 
animals (119). Given these results, future IF studies should be cautious when recruiting 
participants with hypothyroidism and should measure changes in thyroid hormones.  
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CHAPTER 5 
DISCUSSION 
 
5.1 Safety, Tolerability, and Comprehension 
 One of the primary concerns when planning the study was the safety of the patients and 
minimizing the risk of hypoglycemia. At the time, we had little data on the risk of hypoglycemia 
during extended fasts in individuals with DM2. Luckily, not a single case of confirmed 
hypoglycemia was reported during the study, and only one case of symptomatic hypoglycemia 
that did not meet criteria for hypoglycemia (SMBG > 4.0 mmol/L) was reported.  
 The majority of participants enjoyed IF, with very few finding the intervention difficult. 
Enjoyment of IF seemed to be tied strongly to self-perceived improvements in SMBG readings. 
Participants that did not find IF tolerable indicated that food temptation and social life were 
challenging, and typically did not see improvements in SMBG. Two of three individuals who 
reported nausea during IF still saw the intervention as enjoyable and successful after medication 
timing was altered. Several individuals commented on the ease of the diet, and a reduction in 
stress compared to regular meal times that require food preparation. Individuals who prepared 
their own meals, and not those who consumed pre-prepared meals (either packaged, prepared in 
a restaurant, or prepared by a family member) reported more satisfaction with IF. This may 
indicate that IF is an ideal dietary intervention to apply in individuals who bear sole 
responsibility for meal preparation and have limited time for meal preparation.  
 As mentioned in Section 1.4, individuals with DM2 are in need of simple and accessible 
nutrition interventions that can be easily taught and do not require baseline knowledge and skills. 
In our study, IF was taught to all the participants in a single session lasting only 15-30 minutes. 
Logbooks indicated that participants understood the intervention and closely adhered to the 
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fasting recommendations. However, the high protein aspect of the dietary intervention was 
problematic. Participants who completed the food photography diaries did not show a significant 
increase in their protein intake above baseline, and did not meet the 1.5g/kg target. However, 
participants did show sharp declines in carbohydrate and fat intake, but not protein intake, which 
may have been a result of the recommendations to consume high protein foods. Compared to the 
IF guidelines, participants required more education on how to increase protein intake, such as 
lists of high protein foods and photographs of high protein meals. IF alone, without the high 
protein diet, proved to be an easy and accessible intervention that required minimal time for 
instruction and had little barriers to comprehension and application.  
 
5.2 Comparison to other Intermittent Fasting Studies 
 Our study was unique in several regards. It was the first study on IF to capture a fluid 
transition (i.e. no washout period) from normal dietary conditions to IF, as well as a follow-up 
period to observe the after effects of IF. It was also the first IF study to observe weight loss 
without applying controls on calorie consumption. Past studies have applied IF either 
eucalorically (57,58), hypocalorically (93), or did not observe weight loss (89,90). Our study was 
also the first on IF to track either daily SMBG or daily hours fasted and make inferences on the 
relationship between those measures. Lastly, it was one of the first nutrition studies to effectively 
make use of the Remote Food Photography Method, which has superior validity compared to 
standard measures of dietary intake (50,51).   
Kahleova et al. (93) provides the most similar study to our own, having applied an IF 
regimen to individuals with DM2 over a 3 month period in a cross-over fashion. This study 
showed similar trends in weight and waist circumference reduction compared to our own study. 
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However, this study showed statistically significant improvements in fasting insulin and lipids 
with IF, whereas our study showed no statistically significant changes due to strikingly different 
responses in lipids (HDL, LDL, TC, TG) and HOMA-IR between participants that did not 
correlate to changes in SMBG, hours fasted, energy intake, or baseline biochemical and 
anthropometric measurements. The intervention applied by Kahleova et al. differed in that 
participants were explicitly instructed to consume meals during the morning and early afternoon, 
as opposed to our own intervention where patients self-selected meal times - frequently opting 
for afternoon and evening meals instead. This difference may have effected biochemical results 
via feeding entrainment (120,121) or through currently unknown biological mechanisms.  
Results from four previous trials in healthy individuals provide insight on the potential of 
feeding entrainment to impact biochemical outcomes (57,58,122–124). Keim et al. demonstrated, 
using a randomized crossover design, that women consuming the majority of their calories at 
night had superior fat-free mass retention and fat mass reduction during a hypocaloric diet when 
compared to women consuming the majority of their calories in the morning (122) – supporting 
our anthropometric findings. However, neither lipids nor insulin sensitivity were measured in 
that study.  
Farshchi et al. tested the effects of breakfast inclusion and breakfast omission on healthy 
women, showing that breakfast omission led to increased fasting LDL, and a larger area under 
the curve of insulin in response to a morning test meal (123) (neither of which are considered 
beneficial shifts) – despite no changes in weight, waist circumference, body fat percentage, or 
resting energy expenditure. However, dietary records in that study indicated that participants 
consumed less energy when breakfast was included vs. excluded. This contrasts the results of our 
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study, where participants saw improvements in anthropometric parameters (Weight, BMI, Waist 
Circumference), and also consumed less energy during IF compared to standard meal patterns.  
Papers published by Stote et al. and Carlson et al. on healthy normal weight individuals 
showed that IF (with one large evening meal only) increased fasting glucose, triglycerides, LDL, 
HDL and total cholesterol, and worsened insulin sensitivity in response to a morning oral 
glucose tolerance test – despite leading to reductions in weight, fat mass, and cortisol levels, with 
no changes in hematologic variables (57,58). Given that reductions in fat mass, weight, and waist 
circumference are typically accompanied by improvements in insulin sensitivity and lipids, it is 
reasonable to question if the positive effects of loss of fat mass on morning fasting lipids, insulin 
and glucose are masked or confounded by the effects of feeding entrainment to morning meal 
exclusion. 
One final piece of evidence comes from Thomas et al., which offers unique insight on 
how regular eating patterns may effect lipid and glucose excursions during meal times (124). In 
that study, the investigators tested the acute effects of breakfast skipping or breakfast inclusion 
on lunchtime biochemical parameters in two groups – regular breakfast eaters and regular 
breakfast skippers. What they found was that regular breakfast eaters, when forced to skip 
breakfast, had greater insulin and free fatty acid excursions in response to lunch and decreased 
fat oxidation after lunch compared to days where they consumed both breakfast and lunch. In 
contrast, regular breakfast skippers did not experience irregular biochemical responses at lunch 
after breakfast omission or breakfast inclusion.  
There is currently little to no feeding entrainment research on humans, but evidence from 
animal studies suggest that central and peripheral biological clocks are altered as a result of shifts 
in feeding schedule (120,121), and that these shifts may impact endogenous lipid and glucose 
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biosynthesis (125). There is currently no evidence in humans regarding the effects of feeding 
entrainment on various morning fasted or 24-hour biochemical readings in any outcomes that 
were measured in this study. Moreover, there is little to no indication if these alterations in 
biological clock regulation are harmful or beneficial to human health in regards to clinical 
endpoints.  
Given these results, there many potential inferences that could be made to explain the 
discrepancy between the observed results in healthy individuals and those with DM2. IF with 
morning meals may lead to metabolic improvements vs. IF with evening meals. IF may affect 
healthy individuals differently than individuals with DM2. IF may exert different biochemical 
and anthropometric effects under eucaloric conditions compared IF in hypocaloric conditions. 
The response to IF may have large inter-individual variances, skewing the results of independent 
IF studies. Deviating from regular temporal meal consumption patterns may impact biochemical 
outcomes. Lastly, all or some of these factors may interact. Further research is warranted to 
discern the true effects of IF from those of feeding entrainment, energy balance, and health 
status.    
 
5.3 Challenges 
5.3.1 Recruitment 
 The most difficult challenge in the study was undoubtedly recruitment, and this led to 
severely underpowered results. This comes as no surprise, since other studies have found that 
more than half of studies never meet recruitment targets (126). Although online advertisements 
proved effective in garnering large view counts (+10,000 views over the study duration) and 
hundreds of e-mail and telephone inquiries, they were not sufficient to meet adequate targets for 
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participant enrollment. Advertisements placed in medical clinics around Saskatoon were 
marginally effective, only providing a small number of telephone consults.  
In the initial exclusion criteria for the first phase of the study, individuals on any 
sulfonylureas were excluded from the study. This was overwhelmingly the primary barrier to 
recruitment, and omitted many interested potential participants during initial telephone consults. 
This was the case despite acquiring the potential participants’ approval to contact their primary 
physician to request a change in medication for the duration of the study. Despite these efforts, 
not a single physician ever replied to the request and none of these participants were recruited for 
the study. After we became aware of the new study by Kahleova et al. (93), which had DM2 
participants on sulfonylureas complete a 3 month trial of IF with no reports of adverse side-
effects, we had sufficient evidence to justify the recruitment of participants on new generation 
sulfonylureas (i.e. Gliclazide). Unfortunately, this wasn’t enacted until the last months of study 
recruitment.  
 Another hurdle in recruitment was the lack of recruitment infrastructure. We were 
declined support from local diabetes nutrition programs, which would have served as an ideal 
center for recruitment and participant education. This may have been due to the stark contrast 
between conventional nutrition interventions for people with DM2 (which promote regular meal 
and snack intake) and IF, as it has been found that studies that investigate clinical interventions 
that are unfamiliar to clinical collaborators are more likely to encounter recruitment problems 
(127). For the first half of recruitment we had no physicians seeking patients for us, and when 
some physicians were eventually enlisted in helping with recruitment very few actually referred 
patients. Future nutrition studies should have both the co-operation of local DM2 nutrition 
programs, as well as physicians who routinely see DM2 patients with more integral roles in the 
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study, such as principle investigator or co-principle investigator. Future studies of low-risk 
lifestyle interventions should seek to incentivize physicians (and other health care workers) not 
in principle study roles to aid in recruitment.  
 
5.3.2 Data Analysis 
 Very few papers have been published on the analysis of SMBG data. Several statistical 
techniques exist for analyzing blood glucose from continuous glucose monitoring (CGM). 
However, SMBG data presents unique problems related to missing data and non-continuity that 
cannot be addressed with statistical techniques developed for CGM. One technique for analyzing 
SMBG data, called the Average Daily Risk Range (ADRR), is only suitable for predicting major 
hypo- or hyper-glycemia (defined as <3.9mmol/L and >10.0mmol/L, respectively). ADRR uses 
3-5 daily SMBG measurements over the course of 1 month to establish blood glucose variability, 
which it then transforms into a risk index to predict future occurrences of hypo- and hyper-
glycemia (128–130). ADRR is only representative of extreme SMBG data, and does little to 
explore smaller deviations or describe the distribution of SMBG data. ADRR would have 
provided an inadequate measure of SMBG in our study, since no hypoglycemic and very few 
hyperglycemic events occurred throughout the entire study period. Lastly, ADRR does not 
reflect blood glucose targets for individuals with diabetes.     
SMBG data presents a unique problem for statistical analysis, particularly for non-linear 
time-series regression. Statistical and non-statistical outliers disproportionately skew the 
regression analysis by contributing more to the sum of squares, effecting the regression line and 
subsequent R
2
 value. Statistical and non-statistical outliers are extremely common in SMBG 
logs, and should not be omitted. A standard, albeit misguided, procedure for dealing with outliers 
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is deletion, but because they are biologically relevant events in SMBG logs these large 
deviations should be retained for analysis. An additional problem lies in standard weighting 
schemes used to enhance the accuracy of regression models that do not adequately address issues 
with SMBG logs. In SMBG data, deviations from the normal glucose range create primarily right 
tails (hyperglycemia). Hyperglycemic events are generally more common than hypoglycemic 
events in T2DM, and are further from ideal glucose ranges. For example: 
(Event: |Normal FPG – Event FPG| = Absolute Difference in FPG) 
Extreme Hypoglycemic event: | 5.0mmol/L – 2.0mmol/L | = 3.0mmol/L 
Mild Hypoglycemic event: | 5.0mmol/L – 3.0mmol/L | = 2.0mmol/L, 
Mild hyperglycemic event: | 5.0mmol/L – 11.0mmol/L | = 6.0mmol/L 
Extreme Hyperglycemic event: | 5.0mmol/L – 18.0mmol/L | = 13.0mmol/L 
This uneven distribution makes SMBG data difficult to properly weight in a biologically relevant 
manner. Most nonlinear weighting procedures operate under the pretence that deviation increases 
as the Y value (i.e. glucose) increases. In the case of SMBG logs, as Y increases the deviation 
may decrease in size largely due to smaller tails (i.e. extreme data points are closer to the mean, 
making the distribution more narrow). The specific combination of statistical procedures 
(Regression, KS test, OLR) described in the methods section was developed in order to address 
these concerns.  
 
5.4 Strengths and Weaknesses 
5.4.1 Internal Validity 
 As explored in the previous section, there is little research on human feeding 
entrainment, its interaction with diurnal rhythms, its influence on fasting morning biochemical 
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parameters, and its impacts on health or lipid and glucose homeostasis. As such, it is difficult to 
interpret the observed alterations in fasting glucose, insulin, and lipids that occurred as a result of 
IF. However, anthropometric changes were in line with previous studies of IF, and the nature of 
our study design allowed us to clearly observe both inter- and intra-individual anthropometric 
changes, which were largely positive. The study design, paired with the daily self-tracking of 
daily hours fasted and SMBG, elucidated the underlying relationship between time spent fasting 
and morning SMBG. However, the lack of relationship between daily hours fasted and afternoon 
and evening SMBG may have been due to a lack of internal validity, namely the inability of the 
study design to account for meal ingestion around afternoon and evening SMBG readings. The 
distributions of afternoon and evening SMBG were markedly wider and right tailed compared to 
morning SMBG. This comes as no surprise, since random glucose measurements are by nature 
more stochastic than fasted morning glucose, given that they may or may not be influenced by 
recent food intake. Lastly, the inclusion of a follow-up phase provided additional insights into 
the nature of IF. The convex and concave models for morning SMBG suggest that any alteration 
(whether positive or negative) in glucose homeostasis is not permanent and quickly reverses 
upon cessation of IF. Likewise, most biochemical and anthropometric parameters regressed 
towards baseline values (albeit sustaining some of the effects of IF) during the follow-up period, 
which may have been due to the lack of clinically significant weight loss (5-10% of bodyweight), 
some of which was regained during the follow-up phase.  
The poor self-reporting of visual analog scales prohibited a reliable analysis of the effects 
of IF on hunger and satiety, and alternative means should be used in future free-living studies to 
gauge hunger and satiety, such as post-hoc hunger and satiety ratings. Other studies that 
successfully used visual analog scales to record hunger and satiety did so via staff attendance at 
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meal times (57). Self-reporting of SMBG readings and continuous fasting hours was 
significantly better than expected in most participants, and could become an integral part of 
future observational research. Coffee and tea intake was poorly reported by most participants, as 
such, it was impossible to determine any effects coffee or tea intake may have had on study 
participants. 
 
5.4.2 External Validity 
 Due to the small sample size in this study, external validity was severely compromised. 
The results of a study on 10 individuals with DM2 cannot be extrapolated to apply to the 
millions of heterogeneous individuals with DM2. The primary significant results, namely 
reductions in weight and BMI, did not reach levels that would be considered clinically relevant 
(i.e. 5-10% decrease in body weight). Participants did significantly reduce their weight, but the 
magnitude was clinically insignificant, as most participants did not change their BMI 
classification.  
Extrapolations from this study are limited to short-term biochemical and anthropometric 
changes. External validity in biomedical research is achieved primarily through research on long-
term health outcomes and clinical endpoints (mortality, cancer, cardiovascular events, etc.), 
which are beyond the scope of this study. Establishing external validity for the effects of IF will 
be accomplished by future trials that are larger in scope and well funded. Ultimately, this study 
will function as preliminary research used to inform future clinical trials.  
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5.4.3 Biases and Conflicts of Interest 
 The investigators of this study claim no conflicts of interest. However, two study 
investigators, Mr. Bowen and Dr. Welihinda, had at one point prior to the study practiced the IF 
meal timing pattern for a period of >2 years each. At no point during the recruitment, data 
collecting, or data analysis was Mr. Bowen practicing IF, but Dr. Welihinda had continued IF 
throughout the duration of the entire study. No other study investigators claimed biases or 
conflicts of interest. 
  
5.5 Future Directions 
 Before further IF research is conducted, investigators should aim to conduct more basic 
research on the interaction between feeding entrainment and 24-hour diurnal biochemical 
patterns. One study, that tested the effects of 2 days per week of very low energy dieting, serves 
as an example of the type of controls that must be implemented (131). In that study, investigators 
captured data on triglycerides and HOMA-IR over five consecutive mornings, with two 
mornings being during low-energy days, and three mornings of ad lib caloric intake. It was 
discovered that HOMA-IR and triglyceride levels undulated in tandem with energy intake, with 
both lowering during low-energy days and rising back to baseline levels during high-energy 
days. Since caloric undulation occurs over the span of a single day during IF, future investigators 
should take blood samples from participants at regular intervals for a full 24-hours and record 
any fluctuations in cardiometabolic risk factors before and after the intervention period. Relying 
entirely on morning fasted readings to determine the effect of IF may result in missing 
significant biochemical changes that occur during peak fasting hours. Future IF investigators 
should also keep in mind the results by Thomas et al. (124) by capturing regular meal time habits 
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before the beginning of the study, and then use that data to sub-divide participants in post-hoc 
analyses.  
Given that most biochemical parameters regressed towards baseline in our study, future 
studies should include longer intervention periods until clinically significant weight loss is 
achieved (>10% of body weight) to see if changes in glucose homeostasis, lipids, and 
inflammation are sustained or improve during follow-up periods.  
Due to the lack of association between the IF intervention and afternoon and evening 
random SMBG, future studies could acquire larger sample sizes to account for the additional 
noise in random SMBG measurements, or by collecting information on meal and snack times in 
tandem with SMBG data to directly explore for effects of food intake on SMBG during IF. 
 
5.6 Conclusion 
A short bout of Intermittent Fasting in a small group of individuals with DM2 led to 
significant group decreases in weight, BMI, and Morning SMBG. Non-significant group 
decreases in waist circumference and CRP were also observed. There was a significant 
association between the percent and total increases in fasting hours during the intervention phase 
and low morning SMBG. However, large variances in response were noted between participants, 
which may have been due to a larger magnitude change in daily hours fasted during the IF phase.  
After IF was ceased most parameters regressed to baseline values. IF was well tolerated in most 
individuals and had minimal to no side effects in most participants when medication timing was 
adjusted. In the five participants who measured food intake and physical activity, IF led to an 
overall decrease in caloric intake as measured by food photography, and had inconsistent 
changes in physical activity as measured by YPAS. It is probable that the observed benefits of IF 
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on anthropometric parameters were a product of a diet-mediated energy deficit, but the cause of 
the large variance observed between participants in biochemical parameters remains unknown.   
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WC 
109.5cm 
-0.35 
kg/m2 
-
1.5cm 
-0.9kg 
+0.35 
kg/m2 
+2cm +0.9kg 
8
7
 
  
J. Participant 10              Morning SMBG 
 
  
                     Baseline-IF      IF-Follow-up 
          
 
 
61 
years  
BMI 
51.5 
WT 
131.8kg 
WC 
134cm 
-1.19 
kg/m2 
-3cm -2.8kg 
+0.45 
kg/m2 
-2cm +0.9kg 
8
8
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K. Photo Food Diary Examples 
Dinner (Before)          Dinner (After) 
  
Breakfast            Lunch 
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K. List of High Protein Foods 
Ground meats 
 ½ cup Beef – 16g Pro 
 ½ cup Pork – 16g Pro 
 ½ cup Chicken – 17g Pro 
 ½ cup Turkey – 18g Pro 
 
Patties 
 4oz Beef Patty – 30g Pro 
 4oz Chicken Patty – 28g Pro 
 4oz Turkey Patty – 24g Pro 
 4oz Pork Sausage Patty – 16g 
 
Beef Lean cuts or wild meats 
 1 oz Round Steak – 8g 
 Deck of cards – 24g Pro 
 
Beef Fatty cuts 
 1 oz Ribeye Steak – 7g 
 Deck of cards – 21g Pro 
 
Sausage 
 1 oz Breakfast Sausage – 5g Pro 
 Deck of cards – 15g Pro 
 1oz Pork Sausage – 3g Pro 
 Deck of cards – 9g Pro  
 
Fish 
 1 oz Salmon or northern pike/walleye – 7g 
 Deck of cards – 21g  
 
Chicken (breast) 
 1 oz – 9g Pro 
 Deck of cards – 27g Pro 
 
Chicken (other) 
Thigh (1 full) – 21g Pro 
 Drumstick (1 full) – 15g Pro 
 Wing (1 full) – 5g Pro 
 
Pork 
 Loin (chops) – 8g/oz 
 Deck of cards – 24g 
 1 Chop (150g) – 43g 
 Ham (Processed) – 5g/oz 
 Deck of cards – 15g 
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 Bacon (1 strip) – 3g 
 
Dairy 
 1 cup Milk – 8g Pro 
1 cup Greek Yogurt – 24g Pro 
 1 cup Plain Yogurt – 14g Pro 
 ½ cup cheese (cheddar, mozza, asiago, brie) – 15g Pro 
 ½ cup feta cheese – 10g Pro 
 
Beans 
 1 cup black beans cooked – 15g Pro 
 1 cup kidney beans cooked – 16g Pro 
 
Tofu  
 ¼ Block – 7g Pro 
 
Lentils 
 1 cup – 52g Pro 
 
Veggie Burger 
 3oz Patty – 11g Pro 
 
